

# CITATION REPORT

List of articles citing

**A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study**

**DOI: 10.1016/j.ajo.2009.01.024**

**American Journal of Ophthalmology, 2009, 148, 43-58.e1.**

**Source:** <https://exaly.com/paper-pdf/46763579/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
769	Wirksamkeit und Sicherheit der transskleralen Anti-VEGF-Eingabe. <b>2009</b> , 23, 249-255		1
768	[Visual self-assessment with the ACTO test during follow-up of AMD patients after intravitreal injections]. <b>2009</b> , 106, 775-82		1
767	The as-needed treatment strategy for choroidal neovascularization: a feedback-based treatment system. <i>American Journal of Ophthalmology</i> , <b>2009</b> , 148, 1-3	4.9	36
766	"Treat and extend" dosing of intravitreal anti-vascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation. <i>Retina</i> , <b>2009</b> , 29, 1424-31	3.6	147
765	Results of 1-year follow-up examinations after intravitreal bevacizumab administration for idiopathic choroidal neovascularization. <i>Retina</i> , <b>2010</b> , 30, 733-8	3.6	21
764	A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO Study. <b>2010</b> , 2010, 133-134		
763	Combined ranibizumab and photodynamic therapy to treat exudative age-related macular degeneration: an option for improving treatment efficiency. <i>Retina</i> , <b>2010</b> , 30, 1190-6	3.6	10
762	Current world literature. <b>2010</b> , 21, 239-46		
761	Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration treated with ranibizumab: 24-month results. <i>Retina</i> , <b>2010</b> , 30, 1017-24	3.6	38
760	Intravitreal bevacizumab for exudative age-related macular degeneration: effect on different subfoveal membranes. <i>Retina</i> , <b>2010</b> , 30, 1426-31	3.6	7
759	Do we need a new classification for choroidal neovascularization in age-related macular degeneration?. <i>Retina</i> , <b>2010</b> , 30, 1333-49	3.6	292
758	Long-term follow-up for type 1 (subretinal pigment epithelium) neovascularization using a modified "treat and extend" dosing regimen of intravitreal anti-vascular endothelial growth factor therapy. <i>Retina</i> , <b>2010</b> , 30, 1368-75	3.6	94
757	Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab. <b>2010</b> , 54, 310-9		32
756	Treatment of age-related macular degeneration: beyond VEGF. <b>2010</b> , 54, 523-8		27
755	Intravitreal bevacizumab for age-related macular degeneration with good visual acuity. <b>2010</b> , 54, 565-70		12
754	Anti-VEGF therapies and blood pressure: more than meets the eye. <b>2010</b> , 12, 33-8		10
753	Three-dimensional analysis of retinal layer texture: identification of fluid-filled regions in SD-OCT of the macula. <b>2010</b> , 29, 1321-30		148

752	Cost-effectiveness of ranibizumab for the treatment of neovascular age-related macular degeneration in Germany: Model analysis from the perspective of Germany's statutory health insurance system. <b>2010</b> , 32, 1343-56		19
751	Imaging chorioretinal vascular disease. <i>Eye</i> , <b>2010</b> , 24, 422-7	4.4	47
750	Retinal angiomatous proliferation or retinal anastomosis to the lesion. <i>Eye</i> , <b>2010</b> , 24, 491-6	4.4	28
749	Neovascular age-related macular degeneration: decision making and optimal management. <i>Eye</i> , <b>2010</b> , 24, 497-505	4.4	19
748	Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration. <i>Clinical Ophthalmology</i> , <b>2010</b> , 4, 1271-5	2.5	18
747	Identifying early recurrence of choroidal neovascularization during treatment with ranibizumab using C-scan. <i>European Journal of Ophthalmology</i> , <b>2010</b> , 20, 559-64	1.9	2
746	Use of nepafenac (Nevanac) in combination with intravitreal anti-VEGF agents in the treatment of recalcitrant exudative macular degeneration requiring monthly injections. <i>Clinical Ophthalmology</i> , <b>2010</b> , 4, 1249-52	2.5	14
745	Lucentis using Visudyne study: determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration. <i>Clinical Ophthalmology</i> , <b>2010</b> , 4, 1073-9	2.5	17
744	Effects of retinal morphology on contrast sensitivity and reading ability in neovascular age-related macular degeneration. <b>2010</b> , 51, 5431-7		38
743	Ranibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional setting. <b>2010</b> , 94, 292-6		54
742	Ranibizumab therapy for neovascular age-related macular degeneration. <b>2010</b> , 363, 1648-55		69
741	Bevacizumab for neovascular age-related macular degeneration (ABC trial): multicenter randomized double-masked study. <b>2010</b> , 3, 747-52		5
740	Alternative anti-VEGF treatment regimens in exudative age-related macular degeneration. <b>2010</b> , 5, 799-809		
739	Antivascular endothelial growth factors in age-related macular degeneration. <b>2010</b> , 46, 21-38		12
738	Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL study. <b>2010</b> , 94, 1611-7		37
737	[Treatment of wet AMD with less than 12 injections of Ranibizumab per year]. <b>2010</b> , 227, 294-7		6
736	[Outer retinal cysts in exudative age-related macular degeneration: a spectral domain OCT study]. <i>Journal Francais DsOphtalmologie</i> , <b>2010</b> , 33, 605-9	0.8	2
735	Retinal imaging and image analysis. <b>2010</b> , 3, 169-208		685

734	Intravitreal dexamethasone as an enhancer for the anti-VEGF treatment in neovascular ARMD: Recovering an old ally. <i>Archivos De La Sociedad Espanola De Oftalmologia</i> , <b>2010</b> , 85, 79-80	0.1	0
733	Long-term visual and anatomical outcomes following anti-VEGF monotherapy for retinal angiomatous proliferation. <b>2010</b> , 94, 701-5		35
732	Evaluation of artifacts associated with macular spectral-domain optical coherence tomography. <b>2010</b> , 117, 1177-1189.e4		86
731	When should anti-vascular endothelial growth factor treatment be stopped in age-related macular degeneration?. <i>American Journal of Ophthalmology</i> , <b>2010</b> , 149, 4-6	4.9	2
730	Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab. <i>American Journal of Ophthalmology</i> , <b>2010</b> , 150, 666-73	4.9	86
729	Intravitreal ranibizumab for choroidal neovascularization in angioid streaks. <i>American Journal of Ophthalmology</i> , <b>2010</b> , 150, 692-700.e1	4.9	37
728	Dexametasona intravítrea como potenciador del tratamiento anti-VEGF en la degeneración macular asociada a la edad neovascular: recuperando un viejo aliado. <i>Archivos De La Sociedad Espanola De Oftalmologia</i> , <b>2010</b> , 85, 79-80	0.5	3
727	Effectiveness of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration in a Canadian retina practice: a retrospective review. <i>Canadian Journal of Ophthalmology</i> , <b>2010</b> , 45, 590-5	1.4	31
726	Intravitreal anti-VEGF treatment in eyes with combined choroidal neovascularisation and vitreomacular traction syndrome. <b>2010</b> , 94, 1205-10		11
725	Bevacizumab versus ranibizumab for the treatment of neovascular age-related macular degeneration. <b>2010</b> , 5, 603-615		1
724	Intravitreal bevacizumab combined with intravitreal triamcinolone for therapy-resistant exudative age-related macular degeneration. <i>Journal of Ocular Pharmacology and Therapeutics</i> , <b>2010</b> , 26, 207-12	2.6	16
723	Cost effectiveness of treatments for wet age-related macular degeneration. <b>2011</b> , 29, 107-31		37
722	Photoresponsive PEG-anthracene grafted hyaluronan as a controlled-delivery biomaterial. <b>2011</b> , 12, 923-32		40
721	Spectral-domain optical coherence tomography as an indicator of fluorescein angiography leakage from choroidal neovascularization. <b>2011</b> , 52, 5579-86		49
720	[Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration]. <i>Journal Francais DeOphthalmologie</i> , <b>2011</b> , 34, 376-81	0.8	2
719	Spectral-domain versus time domain optical coherence tomography before and after ranibizumab for age-related macular degeneration. <b>2011</b> , 46, 152-9		11
718	Management of Neovascular AMD. <b>2011</b> , 79-98		
717	Automatic characterization of classic choroidal neovascularization by using AdaBoost for supervised learning. <b>2011</b> , 52, 2767-74		17

716	Review of ranibizumab trials for neovascular age-related macular degeneration. <b>2011</b> , 26, 372-9		27
715	Bevacizumab versus ranibizumab for AMD. <b>2011</b> , 364, 1966-7		58
714	Therapeutic efficacy of bevacizumab for age-related macular degeneration: what are the implications of CATT for routine management?. <b>2011</b> , 28, 853-65		7
713	Intravitreal ranibizumab for myopic choroidal neovascularization: factors predictive of visual outcome and need for retreatment. <i>American Journal of Ophthalmology</i> , <b>2011</b> , 151, 529-34	4.9	48
712	Cystoid macular degeneration in exudative age-related macular degeneration. <i>American Journal of Ophthalmology</i> , <b>2011</b> , 152, 100-107.e2	4.9	18
711	A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy. <i>American Journal of Ophthalmology</i> , <b>2011</b> , 152, 784-92.e2	4.9	66
710	[Assessment of the effectiveness and safety of ranibizumab in neovascular age-related macular degeneration]. <b>2011</b> , 136, 471-7		
709	Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. <b>2011</b> , 56, 95-113		209
708	Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. <b>2011</b> , 118, 523-30		203
707	The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. <b>2011</b> , 118, 1098-106		122
706	Predicting visual outcomes for macular disease using optical coherence tomography. <b>2011</b> , 25, 145-58		23
705	Age-related macular degeneration. <i>Clinical Ophthalmology</i> , <b>2011</b> , 5, 593-601	2.5	8
704	Preferential hyperacuity perimeter as a functional tool for monitoring exudative age-related macular degeneration in patients treated by intravitreal ranibizumab. <b>2011</b> , 52, 7012-8		14
703	Evaluation of patients' experiences at different stages of the intravitreal injection procedure - what can be improved?. <i>Clinical Ophthalmology</i> , <b>2011</b> , 5, 1499-502	2.5	29
702	Endogenic regulation of proliferation and zinc transporters by pigment epithelial cells nonvirally transfected with PEDF. <b>2011</b> , 52, 5400-7		5
701	Management of neovascular age-related macular degeneration in clinical practice: initiation, maintenance, and discontinuation of therapy. <b>2011</b> , 2011, 752543		3
700	One-year outcomes using ranibizumab for neovascular age-related macular degeneration: results of a prospective and retrospective observational multicentre study. <b>2011</b> , 2011, 405724		37
699	Assessing Errors Inherent in OCT-Derived Macular Thickness Maps. <b>2011</b> , 2011, 692574		42

698	Combined treatment of photodynamic therapy and bevacizumab for choroidal neovascularization secondary to age-related macular degeneration. <b>2011</b> , 25, 231-7		8
697	One-year outcomes of less frequent bevacizumab in age-related macular degeneration. <i>Retina</i> , <b>2011</b> , 31, 645-53	3.6	12
696	Ranibizumab for the treatment of exudative age-related macular degeneration associated with retinal pigment epithelial tear. <i>Retina</i> , <b>2011</b> , 31, 1083-8	3.6	8
695	Current world literature. <b>2011</b> , 22, 205-13		
694	Increasing costs of imaging and treatment of subfoveal choroidal neovascularization in the anti-vascular endothelial growth factor era. <i>Retina</i> , <b>2011</b> , 31, 819-20	3.6	
693	Intravitreal ranibizumab for polypoidal choroidal vasculopathy with recurrent or residual exudation. <i>Retina</i> , <b>2011</b> , 31, 1589-97	3.6	28
692	Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). <i>Retina</i> , <b>2012</b> , 32, 434-57	3.6	155
691	Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization. <i>Retina</i> , <b>2011</b> , 31, 871-9	3.6	68
690	One-year results of a flexible regimen with ranibizumab therapy in macular degeneration: relationship with the number of injections. <i>Retina</i> , <b>2011</b> , 31, 1261-7	3.6	19
689	Preferred therapies for neovascular age-related macular degeneration. <b>2011</b> , 22, 199-204		21
688	Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration. <i>Retina</i> , <b>2011</b> , 31, 26-30	3.6	120
687	Systemic safety of bilateral intravitreal anti-vascular endothelial growth factor injections. <i>Retina</i> , <b>2011</b> , 31, 1-3	3.6	23
686	Ranibizumab monotherapy versus single-session verteporfin photodynamic therapy combined with as-needed ranibizumab treatment for the management of neovascular age-related macular degeneration. <i>Retina</i> , <b>2011</b> , 31, 636-44	3.6	16
685	Age-related macular degeneration: review of current treatments. <b>2011</b> , 6, 195-201		1
684	Anti-VEGF compounds in the treatment of neovascular age related macular degeneration. <b>2011</b> , 12, 173-81		77
683	Visual acuity outcomes in ranibizumab-treated neovascular age-related macular degeneration; stratified by baseline vision. <b>2011</b> , 39, 5-8		20
682	Individual recurrence intervals after anti-VEGF therapy for age-related macular degeneration. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2011</b> , 249, 645-52	3.8	28
681	Results of flexible ranibizumab treatment in age-related macular degeneration and search for parameters with impact on outcome. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2011</b> , 249, 653-62	3.8	32

680 Leitlinien zur Behandlung der feuchten Makuladegeneration. **2011**, 25, 51-55

- 679 [New aspects in the treatment of neovascular age-related macular degeneration: the criteria of re-treatment with the anti-VEGF therapy.]. **2011**, 108, 85-90 3
- 678 Altersabhängige Makuladegeneration. **2011**, 2 2
- 677 Preferential hyperacuity perimeter in assessing responsiveness to ranibizumab therapy for exudative age-related macular degeneration. **2011**, 95, 986-91 9
- 676 [New options in the therapy for neovascular age-related macular degeneration: criteria for repeat treatment in anti-VEGF therapy - current supplementary statement of the Retinological Society, The German Ophthalmological Society and the Professional Association of Ophthalmologists in Germany]. **2011**, 228, 138-43 3
- 675 In vivo evaluation of laser-induced choroidal neovascularization using spectral-domain optical coherence tomography. **2011**, 52, 3880-7 69
- 674 CATT: Into the eye of a tiger. **2011**, 95, 761 2
- 673 Simple estimation of clinically relevant lesion volumes using spectral domain-optical coherence tomography in neovascular age-related macular degeneration. **2011**, 52, 7792-8 8
- 672 Computerized repeating and averaging improve the test-retest variability of ETDRS visual acuity measurements: implications for sensitivity and specificity. **2011**, 52, 9397-402 15
- 671 Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration. **2011**, 95, 386-90 39
- 670 Results of one-year follow-up examinations after intravitreal bevacizumab administration for chronic central serous chorioretinopathy. **2011**, 225, 37-40 41
- 669 Ranibizumab treatment for choroidal neovascularization from causes other than age-related macular degeneration and pathological myopia. **2011**, 225, 81-8 28
- 668 Systemic adverse drug reactions secondary to anti-VEGF intravitreal injection in patients with neovascular age-related macular degeneration. **2011**, 9, 629-46 28
- 667 Subjective and functional deterioration in recurrences of neovascular AMD are often preceded by morphologic changes in optic coherence tomography. **2011**, 95, 1424-6 12
- 666 Comparison of long-acting bevacizumab formulations in the treatment of choroidal neovascularization in a rat model. *Journal of Ocular Pharmacology and Therapeutics*, **2011**, 27, 219-24 2.6 50
- 665 The past, present, and future of exudative age-related macular degeneration treatment. **2012**, 19, 43-51 13
- 664 Combination therapy with low-dose transpupillary thermotherapy and intravitreal ranibizumab for neovascular age-related macular degeneration: a 24-month prospective randomised clinical study. **2012**, 96, 714-8 15
- 663 Management of immediate and sustained intraocular pressure rise associated with intravitreal antivascular endothelial growth factor injection therapy. **2012**, 23, 105-10 27

662 Current world literature. **2012**, 23, 235-40

661	Preferred therapies for neovascular age-related macular degeneration. <b>2012</b> , 23, 182-8		43
660	An Update on Intravitreal Injections for Macular Diseases: Friend or Foe?. <b>2012</b> , 1, 43-50		
659	The VEGF pathway in cancer and disease: responses, resistance, and the path forward. <b>2012</b> , 2, a006593		140
658	Ranibizumab for age-related macular degeneration. <b>2012</b> , 12, 371-81		22
657	Action on AMD. Optimising patient management: act now to ensure current and continual delivery of best possible patient care. <i>Eye</i> , <b>2012</b> , 26 Suppl 1, S2-21	4.4	36
656	Consensus on the diagnosis, treatment and follow-up of patients with age-related macular degeneration eligible for ranibizumab. <b>2012</b> , 7, 219-225		5
655	The 12-month outcome of three consecutive monthly intravitreal injections of ranibizumab for myopic choroidal neovascularization. <i>Journal of Ocular Pharmacology and Therapeutics</i> , <b>2012</b> , 28, 129-33 <sup>2.6</sup>		12
654	Intravitreal ranibizumab versus thermal laser photocoagulation in the treatment of extrafoveal classic choroidal neovascularization secondary to age-related macular degeneration. <b>2012</b> , 228, 93-101		9
653	Choroidal neovascularisation complicating geographic atrophy in age-related macular degeneration. <b>2012</b> , 96, 1479-83		13
652	Triamcinolone and bevacizumab as adjunctive therapies to panretinal photocoagulation for proliferative diabetic retinopathy. <b>2012</b> , 2012, 267643		7
651	Two-year course of subfoveal pigment epithelial detachment in eyes with age-related macular degeneration and visual acuity better than 20/40. <b>2012</b> , 228, 102-9		27
650	Choroidal neovascularization regression on fluorescein angiography after VEGF blockade. <b>2012</b> , 3, 384-8		3
649	Anti-Vascular Endothelial Growth Factor (VEGF) Treatment of Age- Related Macular Degeneration. <b>2012</b> , 7, 90-95		
648	Three-year safety and visual acuity results of epimacular 90 strontium/90 yttrium brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration. <i>Retina</i> , <b>2012</b> , 32, 10-8	3.6	25
647	Sustained increased intraocular pressure related to intravitreal anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration. <b>2012</b> , 21, 241-7		98
646	Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity. <i>Retina</i> , <b>2012</b> , 32, 1250-9	3.6	21
645	PROGNOSTIC FACTORS FOR VISUAL OUTCOME AFTER INTRAVITREAL ANTI-VEGF INJECTION FOR NAIVE MYOPIC CHOROIDAL NEOVASCULARIZATION. <i>Retina</i> , <b>2012</b> , 32, 949-955	3.6	24



644	OPTIMIZING INDIVIDUALIZED THERAPY WITH BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , <b>2012</b> ,	3.6	4
643	Intravitreal bevacizumab treatment for exudative age-related macular degeneration with good visual acuity. <i>Retina</i> , <b>2012</b> , 32, 1811-20	3.6	9
642	Effectiveness at 1 year of monthly versus variable-dosing intravitreal ranibizumab in the treatment of choroidal neovascularization secondary to age-related macular degeneration. <i>Retina</i> , <b>2012</b> , 32, 293-8	3.6	10
641	Causes of unsuccessful ranibizumab treatment in exudative age-related macular degeneration in clinical settings. <i>Retina</i> , <b>2012</b> , 32, 1480-5	3.6	32
640	Combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy. <i>Retina</i> , <b>2012</b> , 32, 1272-9	3.6	18
639	Age-related macular degeneration. <b>2012</b> , 379, 1728-38		1134
638	Three-dimensional segmentation of fluid-associated abnormalities in retinal OCT: probability constrained graph-search-graph-cut. <b>2012</b> , 31, 1521-31		138
637	Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study). <b>2012</b> , 119, 1867-73		54
636	Neovascular age-related macular degeneration. <b>2012</b> , 227 Suppl 1, 11-20		49
635	The significance of early treatment of exudative age-related macular degeneration: 12 months' results. <b>2012</b> , 124, 750-5		2
634	[Management of age-related macular degeneration. An update]. <b>2012</b> , 47, 214-9		1
633	Aflibercept: a Potent Vascular Endothelial Growth Factor Antagonist for Neovascular Age-Related Macular Degeneration and Other Retinal Vascular Diseases. <b>2012</b> , 2, 3		16
632	[Efficacy of prophylactic treatment of intraocular pressure spikes due to intravitreal injections]. <i>Journal Francais DsOphtalmologie</i> , <b>2012</b> , 35, 614-21	0.8	8
631	[New treatment protocols and follow-up in patients with exudative age-related macular degeneration]. <i>Archivos De La Sociedad Espanola De Oftalmologia</i> , <b>2012</b> , 87 Suppl 1, 10-7	0.5	6
630	Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age-related macular degeneration. <b>2012</b> , 53, 1152-61		20
629	Vascular endothelial growth factors in retinal and choroidal neovascular diseases. <b>2012</b> , 44, 1-17		36
628	[Long-term visual acuity in patients with age-related macular degeneration and persistence of subretinal fluid after treatment with ranibizumab]. <i>Archivos De La Sociedad Espanola De Oftalmologia</i> , <b>2012</b> , 87, 237-46	0.5	1
627	Analysis of outcomes for intravitreal bevacizumab in the treatment of choroidal neovascularization secondary to ocular histoplasmosis. <b>2012</b> , 119, 327-32		26

626	HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. <b>2012</b> , 119, 1175-83		272
625	Macular epiretinal brachytherapy in treated age-related macular degeneration: MERITAGE study: twelve-month safety and efficacy results. <b>2012</b> , 119, 1425-31		36
624	Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact. <i>American Journal of Ophthalmology</i> , <b>2012</b> , 153, 468-473.e1	4.9	61
623	Fixed-interval versus OCT-guided variable dosing of intravitreal bevacizumab in the management of neovascular age-related macular degeneration: a 12-month randomized prospective study. <i>American Journal of Ophthalmology</i> , <b>2012</b> , 153, 481-489.e1	4.9	20
622	Combined intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation. <i>American Journal of Ophthalmology</i> , <b>2012</b> , 153, 504-514.e1	4.9	21
621	One-year results of three monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patients. <i>American Journal of Ophthalmology</i> , <b>2012</b> , 154, 117-124.e1	4.9	65
620	Ocular hypertension following intravitreal anti-vascular endothelial growth factor agents. <b>2012</b> , 29, 949-56		24
619	Aflibercept in wet age-related macular degeneration: a perspective review. <b>2012</b> , 3, 153-61		28
618	Sleeping Beauty transposon-mediated transfection of retinal and iris pigment epithelial cells. <b>2012</b> , 53, 4787-96		28
617	Retinal pigment epithelium tears in age-related macular degeneration treated with antiangiogenic drugs: a controlled study with long follow-up. <b>2012</b> , 228, 78-83		20
616	Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration. <b>2012</b> , 13, 1037-53		22
615	Age-related macular degeneration. <b>2012</b> , 724, 15-36		63
614	Evaluation of age-related macular degeneration with optical coherence tomography. <b>2012</b> , 57, 389-414		177
613	Long-term visual acuity in patients with age-related macular degeneration and persistence of subretinal fluid after treatment with ranibizumab. <i>Archivos De La Sociedad Espanola De Oftalmologia</i> , <b>2012</b> , 87, 237-246	0.1	
612	[Bevacizumab versus ranibizumab: a draw?]. <i>Journal Francais D'Ophthalmologie</i> , <b>2012</b> , 35, 79-81	0.8	0
611	In vivo, in vitro toxicity and in vitro angiogenic inhibition of sunitinib malate. <b>2012</b> , 37, 567-74		14
610	Impact of loading phase, initial response and CFH genotype on the long-term outcome of treatment for neovascular age-related macular degeneration. <i>PLoS ONE</i> , <b>2012</b> , 7, e42014	3.7	30
609	Retinal ganglion cell function after repeated intravitreal injections of ranibizumab in patients with age-related macular degeneration. <i>Clinical Ophthalmology</i> , <b>2012</b> , 6, 1073-82	2.5	17

608	New Approach of Anti-VEGF Agents for Age-Related Macular Degeneration. <b>2012</b> , 2012, 637316		11
607	Fixed Monthly versus Less Frequent Ranibizumab Dosing and Predictors of Visual Response in Exudative Age-Related Macular Degeneration. <b>2012</b> , 2012, 690641		8
606	Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability. <b>2012</b> , 2012, 852183		32
605	Treatment of Neovascular Age Related Macular Degeneration. <b>2012</b> ,		
604	Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting. <i>Clinical Ophthalmology</i> , <b>2012</b> , 6, 1149-57	2.5	16
603	Anti-VEGF Treatment Strategies for Wet AMD. <b>2012</b> , 2012, 786870		102
602	Anti-Angiogenic Treatment for Exudative Age-Related Macular Degeneration: New Strategies are Underway. <b>2012</b> , 1, 318-334		5
601	Two-year follow-up of ranibizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy. <i>Clinical Ophthalmology</i> , <b>2012</b> , 6, 1633-8	2.5	13
600	A prospective pilot study comparing combined intravitreal ranibizumab and half-fluence photodynamic therapy with ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration. <i>Clinical Ophthalmology</i> , <b>2012</b> , 6, 1519-25	2.5	8
599	Comparison of the effect between pegaptanib and ranibizumab on exudative age-related macular degeneration with small lesion size. <i>Clinical Ophthalmology</i> , <b>2012</b> , 6, 365-8	2.5	5
598	Spectral domain OCT versus time domain OCT in the evaluation of macular features related to wet age-related macular degeneration. <i>Clinical Ophthalmology</i> , <b>2012</b> , 6, 219-23	2.5	15
597	The intravitreal injection: Variations in regulations, cost and reimbursement in Europe. <b>2012</b> , 26, 2-6		6
596	Interobserver variability for retreatment indications after Ranibizumab loading doses in neovascular age-related macular degeneration. <i>Acta Ophthalmologica</i> , <b>2012</b> , 90, 49-55	3.7	8
595	Is quantitative spectral-domain superior to time-domain optical coherence tomography (OCT) in eyes with age-related macular degeneration?. <i>Acta Ophthalmologica</i> , <b>2012</b> , 90, 620-7	3.7	13
594	Impact of scanning density on spectral domain optical coherence tomography assessments in neovascular age-related macular degeneration. <i>Acta Ophthalmologica</i> , <b>2012</b> , 90, e274-80	3.7	15
593	Efficacy and safety of recombinant tissue plasminogen activator and gas versus bevacizumab and gas for subretinal haemorrhage. <i>Acta Ophthalmologica</i> , <b>2013</b> , 91, 274-8	3.7	17
592	Optimising assessment intervals improves visual outcomes in ranibizumab-treated age-related neovascular degeneration: using the stability phase as a benchmark. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2013</b> , 251, 2327-30	3.8	3
591	Two-year results of combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2013</b> , 251, 2099-1108	3.8	35

590	Prospective study evaluating the predictability of need for retreatment with intravitreal ranibizumab for age-related macular degeneration. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2013</b> , 251, 697-704	3.8	40
589	Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2013</b> , 251, 453-8	3.8	55
588	Maintenance therapy with pegaptanib sodium for neovascular age-related macular degeneration: an exploratory study in Japanese patients (LEVEL-J study). <b>2013</b> , 57, 417-23		7
587	Ranibizumab: a review of its use in the treatment of neovascular age-related macular degeneration. <b>2013</b> , 30, 331-58		35
586	A 4-year longitudinal study of 555 patients treated with ranibizumab for neovascular age-related macular degeneration. <b>2013</b> , 120, 2630-2636		82
585	[Treatment of recurrent neovascular age-related macular degeneration with ranibizumab according to the PrONTO scheme]. <b>2013</b> , 110, 740-5		3
584	Aflibercept for the treatment of age-related macular degeneration. <b>2013</b> , 2, 89-98		22
583	Treatment Paradigms in Neovascular AMD. <b>2013</b> , 1, 12-19		
582	Decisional answer tree analysis of exudative age-related macular degeneration treatment outcomes. <i>International Ophthalmology</i> , <b>2013</b> , 33, 467-74	2.2	2
581	Current anti-vascular endothelial growth factor dosing regimens: benefits and burden. <b>2013</b> , 120, S3-7		71
580	Stereotactic radiotherapy for neovascular age-related macular degeneration: 52-week safety and efficacy results of the INTREPID study. <b>2013</b> , 120, 1893-900		50
579	Anti-vascular endothelial growth factor monotherapy in the treatment of submacular hemorrhage secondary to polypoidal choroidal vasculopathy. <i>American Journal of Ophthalmology</i> , <b>2013</b> , 156, 524-531.e9	4.9	29
578	Vascular endothelial growth factor a in intraocular vascular disease. <b>2013</b> , 120, 106-14		275
577	Different anti-vascular endothelial growth factor treatments and regimens and their outcomes in neovascular age-related macular degeneration: a literature review. <b>2013</b> , 97, 1497-507		36
576	Two-year results of reduced-fluence photodynamic therapy combined with intravitreal ranibizumab for typical age-related macular degeneration and polypoidal choroidal vasculopathy. <b>2013</b> , 57, 283-93		29
575	[Therapy of stage III retinal angiomatous proliferation. Intravitreal ranibizumab injections]. <b>2013</b> , 110, 1171-8		4
574	Two-year results of combined intravitreal anti-VEGF agents and photodynamic therapy for retinal angiomatous proliferation. <b>2013</b> , 57, 211-20		9
573	Optical Coherence Tomography. <b>2013</b> , 82-110		4

572	Vascular endothelial growth factor and its inhibitor in age-related macular degeneration. <b>2013</b> , 3, 128-133		2
571	Fixation stability measurements in patients with neovascular age-related macular degeneration treated with ranibizumab. <i>Canadian Journal of Ophthalmology</i> , <b>2013</b> , 48, 394-9	1.4	18
570	Neovascular age-related macular degeneration: individualizing therapy in the era of anti-angiogenic treatments. <b>2013</b> , 120, S23-5		7
569	Computerized assessment of intraretinal and subretinal fluid regions in spectral-domain optical coherence tomography images of the retina. <i>American Journal of Ophthalmology</i> , <b>2013</b> , 155, 277-286.e1	4.9	48
568	Intravitreal anti-vascular endothelial growth factor therapy versus photodynamic therapy for idiopathic choroidal neovascularization. <i>American Journal of Ophthalmology</i> , <b>2013</b> , 155, 713-9, 719.e1	4.9	29
567	Combination therapy for neovascular age-related macular degeneration refractory to anti-vascular endothelial growth factor agents. <b>2013</b> , 120, 2029-34		53
566	[Intravitreal injection of bevacizumab for naive myopic choroidal neovascularization: 19-month results]. <i>Journal Francais DsOphtalmologie</i> , <b>2013</b> , 36, 12-8	0.8	0
565	Retreatment by series of three intravitreal injections of ranibizumab in neovascular age-related macular degeneration: long-term outcomes. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2013</b> , 251, 1901-7	3.8	2
564	An update on the pharmacotherapy of neovascular age-related macular degeneration. <b>2013</b> , 14, 1017-28		33
563	Aflibercept (VEGF Trap-Eye) for the treatment of exudative age-related macular degeneration. <b>2013</b> , 6, 103-13		18
562	The SECURE study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration. <b>2013</b> , 120, 130-9		73
561	Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. <b>2013</b> , 120, 1046-56		346
560	Pharmacotherapy of Age-Related Macular Degeneration. <b>2013</b> , 1213-1255		5
559	VEGF-A polymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration. <b>2013</b> , 14, 623-30		23
558	Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications. <b>2013</b> , 16, 101-11		54
557	Regenerative nanomedicine for vision restoration. <b>2013</b> , 88, 1480-90		20
556	Anti-VEGF Therapy for AMD: Results and Guidelines. <b>2013</b> , 233-245		1
555	Anti-vascular endothelial growth factor for neovascular glaucoma. <b>2013</b> , CD007920		37

554	Assessment of a spectral domain OCT segmentation software in a retrospective cohort study of exudative AMD patients. <b>2013</b> , 229, 80-5		4
553	Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab. <b>2013</b> , 97, 1032-5		133
552	Two-year results of intravitreal ranibizumab for polypoidal choroidal vasculopathy with recurrent or residual exudation. <i>Eye</i> , <b>2013</b> , 27, 931-9	4.4	4
551	Intravitreal aflibercept for neovascular age-related macular degeneration. <b>2013</b> , 5, 121-30		7
550	Prevention and treatment of age-related macular degeneration: an update for pharmacists. <b>2013</b> , 28, 723-37		7
549	[Choroidal neovascularisation in pathological myopia: epidemiological data from a health services research study conducted in Germany]. <b>2013</b> , 230, 707-14		2
548	Anti-vascular endothelial growth factor in age-related macular degeneration: puzzle or a silent beginning!. <b>2013</b> , 61, 475-8		2
547	Bevacizumab versus Ranibizumab on As-Needed Treatment Regimen for Neovascular Age-Related Macular Degeneration in Turkish Patients. <b>2013</b> , 2013, 151027		6
546	Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme. <b>2013</b> , 97, 1161-7		71
545	Results of 2 years of treatment with as-needed ranibizumab reinjection for polypoidal choroidal vasculopathy. <b>2013</b> , 97, 617-21		44
544	Ocular and systemic safety of bevacizumab and ranibizumab in patients with neovascular age-related macular degeneration. <b>2013</b> , 24, 205-12		23
543	Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. <i>Retina</i> , <b>2013</b> , 33, 1605-12	3.6	145
542	Interleukin 8 promoter polymorphism predicts the initial response to bevacizumab treatment for exudative age-related macular degeneration. <i>Retina</i> , <b>2013</b> , 33, 1815-27	3.6	30
541	VISUAL AND ANATOMICAL OUTCOMES OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION AND VITREOMACULAR INTERFACE DISEASE. <i>Retina</i> , <b>2013</b> , 33, 1359-1364	3.6	3
540	A 12-month prospective trial of inject and extend regimen for ranibizumab treatment of age-related macular degeneration. <i>Retina</i> , <b>2013</b> , 33, 1351-8	3.6	54
539	Effect of optical coherence tomography scan decentration on macular center subfield thickness measurements. <b>2013</b> , 54, 4512-8		9
538	Treatment of exudative age-related macular degeneration with intravitreal ranibizumab in clinical practice: a 3-year follow-up. <b>2013</b> , 229, 158-67		11
537	Relationship between visual acuity and spectral domain optical coherence tomography retinal parameters in neovascular age-related macular degeneration. <b>2014</b> , 231, 37-44		32

536	Characterization of neovascular age-related macular degeneration patients with outer retinal tubulations. <b>2013</b> , 229, 147-51		25
535	Implementation studies of ranibizumab for neovascular age-related macular degeneration. <i>Acta Ophthalmologica</i> , <b>2013</b> , 91 Thesis7, 1-22	3.7	5
534	Three-year visual outcome and injection frequency of intravitreal ranibizumab therapy for neovascular age-related macular degeneration. <b>2013</b> , 230, 27-33		15
533	Endothelial progenitor cells and plasma vascular endothelial growth factor and stromal cell-derived factor-1 during ranibizumab treatment for neovascular age-related macular degeneration. <i>Journal of Ocular Pharmacology and Therapeutics</i> , <b>2013</b> , 29, 530-8	2.6	10
532	One-year results of treatment with bevacizumab alone or ranibizumab alone for low visual acuity due to neovascular age-related macular degeneration. <i>Journal of Ocular Pharmacology and Therapeutics</i> , <b>2013</b> , 29, 865-9	2.6	3
531	â€œProactiveâ€ versus â€œreactiveâ€ anti-VEGF therapies for neovascular age-related macular degeneration: pros and cons. <b>2013</b> , 8, 321-326		1
530	Ophthalmology and the Ageing Society. <b>2013</b> ,		1
529	Effect of topical pressure-lowering medication on prevention of intraocular pressure spikes after intravitreal injection. <i>European Journal of Ophthalmology</i> , <b>2013</b> , 23, 277-83	1.9	14
528	Information used to decide on retreatment of exudative age-related macular degeneration with anti-VEGF in clinical practice. <i>European Journal of Ophthalmology</i> , <b>2012</b> , 0	1.9	2
527	Anatomical measures as predictors of visual outcomes in ranibizumab-treated eyes with neovascular age-related macular degeneration. <i>Retina</i> , <b>2013</b> , 33, 23-34	3.6	51
526	Long-term results of intravitreal ranibizumab treatment for neovascular age-related macular degeneration in clinical practice. <b>2013</b> , 8, 37-40		1
525	Ranibizumab for choroidal neovascularization associated with adult-onset foveomacular vitelliform dystrophy: one-year results. <i>Retina</i> , <b>2013</b> , 33, 513-21	3.6	26
524	Factors predictive of outcomes 1 year after 3 monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patients. <i>Retina</i> , <b>2013</b> , 33, 1949-58	3.6	17
523	Correlation of foveal microstructural changes with vision after anti-vascular endothelial growth factor therapy in age-related macular degeneration. <i>Retina</i> , <b>2013</b> , 33, 964-70	3.6	11
522	Variable response of vascularized pigment epithelial detachments to ranibizumab based on lesion subtypes, including polypoidal choroidal vasculopathy. <i>Retina</i> , <b>2013</b> , 33, 990-7	3.6	32
521	Quantitative changes in retinal pigment epithelial detachments as a predictor for retreatment with anti-VEGF therapy. <i>Retina</i> , <b>2013</b> , 33, 459-66	3.6	25
520	[Long-term treatment with intravitreal ranibizumab for exudative age-related macular degeneration]. <b>2013</b> , 154, 1790-7		1
519	Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study. <i>Clinical Ophthalmology</i> , <b>2013</b> , 7, 1849-58	2.5	43

518	Effect of ranibizumab on serous and vascular pigment epithelial detachments associated with exudative age-related macular degeneration. <b>2013</b> , 7, 565-9		24
517	The results of switching between 2 anti-VEGF drugs, bevacizumab and ranibizumab, in the treatment of neovascular age-related macular degeneration. <i>European Journal of Ophthalmology</i> , <b>2013</b> , 23, 553-7	1.9	22
516	Foveal thickness between stratus and spectralis optical coherence tomography in retinal diseases. <b>2013</b> , 27, 268-75		16
515	Bevacizumab Monotherapy Versus Combined Therapy with Photodynamic Therapy for Occult Choroidal Neovascularization in Age-Related Macular Degeneration. <b>2013</b> , 54, 1554		
514	Initial non-responders to ranibizumab in the treatment of age-related macular degeneration (AMD). <i>Clinical Ophthalmology</i> , <b>2013</b> , 7, 1487-90	2.5	36
513	Emerging roles for antiangiogenesis factors in management of ocular disease. <i>Clinical Ophthalmology</i> , <b>2013</b> , 6, 533-43	2.5	15
512	Two-year outcomes of pro re nata ranibizumab monotherapy for exudative age-related macular degeneration in Japanese patients. <i>Clinical Ophthalmology</i> , <b>2013</b> , 7, 757-63	2.5	2
511	Visual performance in patients with neovascular age-related macular degeneration undergoing treatment with intravitreal ranibizumab. <b>2013</b> , 2013, 268438		15
510	Is spectral-domain optical coherence tomography essential for flexible treatment regimens with ranibizumab for neovascular age-related macular degeneration?. <b>2013</b> , 2013, 786107		3
509	The role of epiretinal membrane on treatment of neovascular age-related macular degeneration with intravitreal bevacizumab. <b>2013</b> , 2013, 958724		5
508	Prospective audit of exudative age-related macular degeneration: 12-month outcomes in treatment-naïve eyes. <b>2013</b> , 54, 5754-60		29
507	Functional characterization and multimodal imaging of treatment-naïve "quiescent" choroidal neovascularization. <b>2013</b> , 54, 6886-92		91
506	Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema. <b>2013</b> , 8, 467-83		29
505	Aflibercept in wet AMD: specific role and optimal use. <b>2013</b> , 7, 711-22		77
504	Improving patient outcomes: role of the primary care optometrist in the early diagnosis and management of age-related macular degeneration. <b>2013</b> , 1		4
503	A delphi study to detect deficiencies and propose actions in real life treatment of neovascular age-related macular degeneration. <b>2014</b> , 2014, 595132		7
502	Bilateral visual outcomes and service utilization of patients treated for 3 years with ranibizumab for neovascular age-related macular degeneration. <i>Clinical Ophthalmology</i> , <b>2014</b> , 8, 717-23	2.5	10
501	Intravitreal anti-VEGF therapy for vascularized pigment epithelium detachment in age-related macular degeneration. <i>European Journal of Ophthalmology</i> , <b>2014</b> , 24, 402-8	1.9	4



500	Reduced fluorescein angiography and fundus photography use in the management of neovascular macular degeneration and macular edema during the past decade. <b>2014</b> , 55, 542-9		20
499	Serum concentration of vascular endothelial growth factor after bilateral intravitreal injection of bevacizumab. <b>2014</b> , 28, 32-8		11
498	Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis. <b>2014</b> , 9, 141-5		12
497	Initial utilization of aflibercept in exudative age-related macular degeneration. <i>European Journal of Ophthalmology</i> , <b>2014</b> , 24, 576-81	1.9	3
496	Intravitreal injection of ranibizumab using a pro re nata regimen for age-related macular degeneration and vision-related quality of life. <i>Clinical Ophthalmology</i> , <b>2014</b> , 8, 1711-6	2.5	11
495	Ranibizumab for the treatment of degenerative ocular conditions. <i>Clinical Ophthalmology</i> , <b>2014</b> , 8, 1187-98	2.5	10
494	The effects of ranibizumab injections on fluorescein angiographic findings and visual acuity recovery in age-related macular degeneration. <i>Clinical Ophthalmology</i> , <b>2014</b> , 8, 981-8	2.5	1
493	Intravitreal Bevacizumab Injection for the Treatment of Choroidal Neovascularization Secondary to Candida Chorioretinitis. <b>2014</b> , 55, 1106		
492	sA population-based study of macular choroidal neovascularization using optical coherence tomography in Eastern China. <b>2014</b> , 8, 371-376		
491	Imaging of naive myopic choroidal neovascularization by spectral-domain optical coherence tomography. <b>2014</b> , 232, 28-36		13
490	A quantitative approach to identify morphological features relevant for visual function in ranibizumab therapy of neovascular AMD. <b>2014</b> , 55, 6623-30		21
489	Outcome of polypoidal choroidal vasculopathy at 1 year by combined therapy of photodynamic therapy with ranibizumab and predictive factors governing the outcome. <i>Eye</i> , <b>2014</b> , 28, 1469-76	4.4	15
488	25th RCOphth Congress, President's Session paper: 25 years of progress in medical retina. <i>Eye</i> , <b>2014</b> , 28, 1041-52	4.4	3
487	Repeatability of retinal thickness and volume metrics in neovascular age-related macular degeneration using the Topcon 3DOCT-1000. <b>2014</b> , 62, 941-8		5
486	Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen. <b>2014</b> , 98, 1192-6		45
485	Retinal pigment epithelium rips after ranibizumab in neovascular age-related macular degeneration: incidence, risk factors and long-term outcome. <b>2014</b> , 231, 432-5		2
484	Macular hole after intravitreal bevacizumab injection for choroidal neovascularisation. <b>2014</b> , 97, 178-80		4
483	Fluorescein angiography and spectral-domain optical coherence tomography for monitoring anti-VEGF therapy in myopic choroidal neovascularization. <b>2014</b> , 52, 25-31		22

482	Relation between changes in foveal choroidal thickness and 1-year results of ranibizumab therapy for polypoidal choroidal vasculopathy. <b>2014</b> , 98, 1201-4		16
481	Poor responders to bevacizumab pharmacotherapy in age-related macular degeneration and in diabetic macular edema demonstrate increased risk for obstructive sleep apnea. <i>Retina</i> , <b>2014</b> , 34, 2423-30	3.6	31
480	Intravitreal anti-vascular endothelial growth factor for retinal angiomatous proliferation in treatment-naïve eyes: long-term functional and anatomical results using a modified PRONTO-style regimen. <i>Retina</i> , <b>2014</b> , 34, 298-305	3.6	35
479	Long-term longitudinal study of patients treated with ranibizumab for neovascular age-related macular degeneration. <b>2014</b> , 25, 158-63		19
478	Anti-VEGF treatment in neovascular age-related macular degeneration: a treat-and-extend protocol over 2 years. <i>Retina</i> , <b>2014</b> , 34, 1531-8	3.6	96
477	Comparison of intravitreal ranibizumab in phakic and pseudophakic neovascular age-related macular degeneration patients with good baseline visual acuity. <i>Retina</i> , <b>2014</b> , 34, 853-9	3.6	6
476	Switching to intravitreal aflibercept injection for polypoidal choroidal vasculopathy refractory to ranibizumab. <i>Retina</i> , <b>2014</b> , 34, 2192-201	3.6	38
475	Results of intravitreal ranibizumab with a prn regimen in the treatment of extrafoveal and juxtafoveal neovascular membranes in age-related macular degeneration. <i>Retina</i> , <b>2014</b> , 34, 860-7	3.6	6
474	Polymorphisms in the APOE gene and the location of retinal fluid in eyes with neovascular age-related macular degeneration. <i>Retina</i> , <b>2014</b> , 34, 2367-75	3.6	2
473	Intravitreal ranibizumab for neovascular age-related macular degeneration patients with good baseline visual acuity and the predictive factors for visual outcomes. <i>Journal Francais DsOphtalmologie</i> , <b>2014</b> , 37, 280-7	0.8	5
472	Repeatability of visual function measures in age-related macular degeneration. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2014</b> , 252, 201-6	3.8	7
471	Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2014</b> , 252, 647-55	3.8	47
470	Comparison of spectral-domain and high-penetration OCT for observing morphologic changes in age-related macular degeneration and polypoidal choroidal vasculopathy. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2014</b> , 252, 3-9	3.8	10
469	Response to anti-VEGF therapy in patients with subretinal fluid and pigment epithelial detachment on spectral-domain optical coherence tomography. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2014</b> , 252, 889-97	3.8	12
468	Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis. <b>2014</b> , 19, 37-48		333
467	Current Strategies for the Management of Treatment-Resistant Neovascular Age-Related Macular Degeneration. <b>2014</b> , 2, 6-13		3
466	Current and investigational pharmacotherapeutic approaches for modulating retinal angiogenesis. <b>2014</b> , 7, 375-91		18
465	Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration. <b>2014</b> , 59, 1-18		100

464	Drug delivery techniques for treating age-related macular degeneration. <b>2014</b> , 11, 61-8		33
463	A safety audit of the first 10 000 intravitreal ranibizumab injections performed by nurse practitioners. <i>Eye</i> , <b>2014</b> , 28, 1161-4	4.4	27
462	A new context: Screen to face distance. <b>2014</b> ,		5
461	Polypoidal choroidal vasculopathy in Caucasian patients with presumed neovascular age-related macular degeneration and poor ranibizumab response. <b>2014</b> , 98, 188-94		64
460	Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. <b>2014</b> , 121, 2181-92		207
459	A safety evaluation of ranibizumab in the treatment of age-related macular degeneration. <b>2014</b> , 13, 1259-70		12
458	Visual acuity and central retinal thickness: fulfilment of retreatment criteria for recurrent neovascular AMD in routine clinical care. <b>2014</b> , 98, 1333-7		5
457	Implants for drug delivery to the posterior segment of the eye: a focus on stimuli-responsive and tunable release systems. <b>2014</b> , 196, 208-21		109
456	[Health services for patients with neovascular age-related macular degeneration in Germany]. <b>2014</b> , 111, 438-42		0
455	Factors influencing the exudation recurrence after cataract surgery in patients previously treated with anti-vascular endothelial growth factor for exudative age-related macular degeneration. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2014</b> , 252, 1573-9	3.8	13
454	Switch to a single dose of aflibercept in bevacizumab nonresponders with AMD. <i>Canadian Journal of Ophthalmology</i> , <b>2014</b> , 49, 431-5	1.4	7
453	Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration. <i>American Journal of Ophthalmology</i> , <b>2014</b> , 157, 1013-21	4.9	76
452	Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. <b>2014</b> , 121, 193-201		532
451	Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration. <b>2014</b> , 121, 1237-45		121
450	Antivascular endothelial growth factor therapies for neovascular age-related macular degeneration: Search for the optimized treatment regimen. <b>2014</b> , 4, 3-8		2
449	Ophthalmic manifestations of inherited neurodegenerative disorders. <b>2014</b> , 10, 349-62		31
448	Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an overview. <b>2014</b> , 13, 785-802		36
447	Artifacts in optical coherence tomography. <b>2014</b> , 28, 81-7		20

446	Radial versus raster spectral-domain optical coherence tomography scan patterns for detection of macular pathology. <i>American Journal of Ophthalmology</i> , <b>2014</b> , 158, 345-353.e2	4.9	15
445	Retention of good visual acuity in eyes with neovascular age-related macular degeneration and chronic refractory subfoveal subretinal fluid. <b>2014</b> , 28, 129-33		21
444	Survey of intravitreal injection techniques and treatment protocols among retina specialists in Canada. <i>Canadian Journal of Ophthalmology</i> , <b>2014</b> , 49, 261-6	1.4	30
443	Gray hyper-reflective subretinal exudative lesions in exudative age-related macular degeneration. <i>American Journal of Ophthalmology</i> , <b>2014</b> , 158, 354-61	4.9	28
442	One-year outcome of two different initial dosing regimens of intravitreal ranibizumab for myopic choroidal neovascularization. <i>Acta Ophthalmologica</i> , <b>2014</b> , 92, e615-20	3.7	20
441	Stereotactic low voltage x-ray radiotherapy for treating neovascular age-related macular degeneration. <b>2014</b> , 9, 153-158		
440	One year results of intravitreal ranibizumab monotherapy for retinal angiomatous proliferation: a comparative analysis based on disease stages. <b>2015</b> , 15, 182		7
439	Triple combination therapy and zeaxanthin for the treatment of neovascular age-related macular degeneration: an interventional comparative study and cost-effectiveness analysis. <i>International Journal of Retina and Vitreous</i> , <b>2015</b> , 1, 22	2.9	4
438	Finding the Optimal Treatment Plan for Exudative AMD: A review of Current Anti-VEGF Dosing Regimens. <i>International Ophthalmology Clinics</i> , <b>2015</b> , 55, 103-12	1.7	1
437	Combined effects of genetic and non-genetic risk factors affect response to ranibizumab in exudative age-related macular degeneration. <i>Acta Ophthalmologica</i> , <b>2015</b> , 93, e451-7	3.7	19
436	OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY VERSUS TRADITIONAL MULTIMODAL IMAGING IN ASSESSING THE ACTIVITY OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION: A New Diagnostic Challenge. <i>Retina</i> , <b>2015</b> , 35, 2219-28	3.6	209
435	IDENTIFICATION OF FLUID ON OPTICAL COHERENCE TOMOGRAPHY BY TREATING OPHTHALMOLOGISTS VERSUS A READING CENTER IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS. <i>Retina</i> , <b>2015</b> , 35, 1303-14	3.6	40
434	TREATMENT OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION WITH RANIBIZUMAB COMBINED WITH KETOROLAC EYEDROPS OR PHOTODYNAMIC THERAPY. <i>Retina</i> , <b>2015</b> , 35, 1547-54	3.6	13
433	EFFECT OF SYSTEMIC BETA-BLOCKERS, ACE INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERS ON DEVELOPMENT OF CHOROIDAL NEOVASCULARIZATION IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , <b>2015</b> , 35, 1964-8	3.6	13
432	Current state of therapeutic strategies with ranibizumab in neovascular age-related macular degeneration. <b>2015</b> , 26, 200-5		
431	Visual outcomes of age-related macular degeneration patients undergoing intravitreal ranibizumab monotherapy in an urban population. <i>Clinical Ophthalmology</i> , <b>2015</b> , 9, 959-65	2.5	5
430	Foveal structure during the induction phase of anti-vascular endothelial growth factor therapy for occult choroidal neovascularization in age-related macular degeneration. <i>Clinical Ophthalmology</i> , <b>2015</b> , 9, 2049-56	2.5	4
429	Individualized Treatment of Neovascular Age-Related Macular Degeneration: What are Patients Gaining? Or Losing?. <b>2015</b> , 4, 1079-101		16

428	Long-Term Visual Outcomes for a Treat and Extend Anti-Vascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration. <b>2015</b> , 4, 1380-402		40
427	Management of neovascular age-related macular degeneration: current state-of-the-art care for optimizing visual outcomes and therapies in development. <i>Clinical Ophthalmology</i> , <b>2015</b> , 9, 1001-15	2.5	24
426	Long-Term Visual Outcome in Wet Age-Related Macular Degeneration Patients Depending on the Number of Ranibizumab Injections. <b>2015</b> , 2015, 820605		7
425	Anti-VEGF Therapy and the Retina: An Update. <b>2015</b> , 2015, 627674		72
424	Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration. <b>2015</b> , 2015, 412903		10
423	Prospective evaluation of teleophthalmology in screening and recurrence monitoring of neovascular age-related macular degeneration: a randomized clinical trial. <b>2015</b> , 133, 276-82		40
422	Blood flow velocity measured using the Retinal Function Imager predicts successful ranibizumab treatment in neovascular age-related macular degeneration: early prospective cohort study. <i>Eye</i> , <b>2015</b> , 29, 630-6	4.4	4
421	Structures affecting recovery of macular function in patients with age-related macular degeneration after intravitreal ranibizumab. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2015</b> , 253, 1201-9	3.8	5
420	Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration. <b>2015</b> , 122, 803-8		91
419	Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD. <b>2015</b> , 15, 40		17
418	Two-year outcomes of "treat and extend" intravitreal therapy for neovascular age-related macular degeneration. <b>2015</b> , 122, 1212-9		116
417	Dégénérescence maculaire liée à l'âge. État des lieux 2015. <b>2015</b> , 8, 118-135		0
416	Comparison of intravitreal ranibizumab between phakic and pseudophakic neovascular age-related macular degeneration patients: Two-year results. <b>2015</b> , 29, 182-6		0
415	Submacular hemorrhage in polypoidal choroidal vasculopathy treated by vitrectomy and subretinal tissue plasminogen activator. <i>American Journal of Ophthalmology</i> , <b>2015</b> , 159, 683-9	4.9	26
414	Prognostic factors of 2-year outcomes of ranibizumab therapy for polypoidal choroidal vasculopathy. <b>2015</b> , 99, 817-22		21
413	Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration. <b>2015</b> , 122, 822-32		122
412	Knockout of A-crystallin inhibits ocular neovascularization. <b>2015</b> , 56, 816-26		16
411	Comparative safety and tolerability of anti-VEGF therapy in age-related macular degeneration. <b>2015</b> , 38, 279-93		15

410	Intravitreal Ranibizumab for neovascular Age-related macular degeneration in clinical practice: five-year treatment outcomes. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2015</b> , 253, 1217-25	3.8	26
409	Refractory subretinal fluid in patients with neovascular age-related macular degeneration treated with intravitreal ranibizumab: visual acuity outcome. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2015</b> , 253, 1211-6	3.8	19
408	Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration: how to alleviate the clinical burden with maintained functional results. <i>Eye</i> , <b>2015</b> , 29, 342-44	4.4	21
407	[Management of aflibercept in routine clinical practice]. <i>Archivos De La Sociedad Espanola De Oftalmologia</i> , <b>2015</b> , 90 Suppl 1, 29-34	0.5	
406	[Oct parameters as predictive factors for the visual outcome after ranibizumab therapy in neovascular age related macular degeneration]. <i>Archivos De La Sociedad Espanola De Oftalmologia</i> , <b>2015</b> , 90, 156-63	0.5	
405	The accuracy of home monitoring to detect disease activity during maintenance therapy for neovascular ARMD. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2015</b> , 253, 1479-83	3.8	3
404	Missed Hospital Appointments of Patients Receiving Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration. <b>2015</b> , 4, 43-9		7
403	Individualized ranibizumab therapy strategies in year 3 after as-needed treatment for polypoidal choroidal vasculopathy. <b>2015</b> , 15, 37		7
402	Comparing different dosing regimens of bevacizumab in the treatment of neovascular macular degeneration: study protocol for a randomised controlled trial. <b>2015</b> , 16, 85		7
401	Outcomes of persistently active neovascular age-related macular degeneration treated with VEGF inhibitors: observational study data. <b>2015</b> , 99, 359-64		13
400	Stereotactic radiotherapy for wet age-related macular degeneration (INTREPID): influence of baseline characteristics on clinical response. <i>Retina</i> , <b>2015</b> , 35, 194-204	3.6	14
399	Intravitreal ranibizumab injections with and without pneumatic displacement for treating submacular hemorrhage secondary to neovascular age-related macular degeneration. <i>Retina</i> , <b>2015</b> , 35, 205-12	3.6	18
398	Comparison of Eylea <sup>®</sup> with Lucentis <sup>®</sup> as first-line therapy in patients with treatment-naïve neovascular age-related macular degeneration in real-life clinical practice: retrospective case-series analysis. <b>2015</b> , 15, 109		13
397	Intravitreal ranibizumab for patients with neovascular age-related macular degeneration with good baseline visual acuity. <b>2015</b> , 233, 27-34		4
396	Oct parameters as predictive factors for the visual outcome after ranibizumab therapy in neovascular age related macular degeneration. <i>Archivos De La Sociedad Espanola De Oftalmologia</i> , <b>2015</b> , 90, 156-163	0.1	
395	Intravitreal Ranibizumab in Daily Clinical Practice for Age-Related Macular Degeneration: Treatment of Exudative Age-Related Macular Degeneration in Real Life. <b>2015</b> , 234, 26-32		8
394	Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept. <b>2015</b> , 32, 797-807		17
393	Evaluating the impact of summer vacation on the visual acuity of AMD patients treated with ranibizumab. <i>Eye</i> , <b>2015</b> , 29, 1453-7	4.4	8

392	Factors Associated with Recurrence of Age-Related Macular Degeneration after Anti-Vascular Endothelial Growth Factor Treatment: A Retrospective Cohort Study. <b>2015</b> , 122, 2303-10		70
391	Intravitreal anti-vascular endothelial growth factor treatment and the risk of thromboembolism. <i>American Journal of Ophthalmology</i> , <b>2015</b> , 160, 569-580.e5	4.9	26
390	Performance of a computerised visual acuity measurement device in subjects with age-related macular degeneration: comparison with gold standard ETDRS chart measurements. <i>Eye</i> , <b>2015</b> , 29, 1085-91	4.4	16
389	Ranibizumab vs. aflibercept for wet age-related macular degeneration: network meta-analysis to understand the value of reduced frequency dosing. <b>2015</b> , 31, 2031-42		16
388	Aflibercept for pigment epithelial detachment for previously treated neovascular age-related macular degeneration. <i>Canadian Journal of Ophthalmology</i> , <b>2015</b> , 50, 373-7	1.4	17
387	Baseline Predictors of 12-Month Treatment Response to Ranibizumab in Patients With Wet Age-Related Macular Degeneration. <i>American Journal of Ophthalmology</i> , <b>2015</b> , 160, 1014-1023.e2	4.9	41
386	Ranibizumab for exudative age-related macular degeneration: A five year study of adherence to follow-up in a real-life setting. <i>Journal Francais DOphtalmologie</i> , <b>2015</b> , 38, 620-7	0.8	55
385	[Interest of optical coherence tomography performed immediately before intravitreal injection of anti-VEGF in exudative AMD]. <i>Journal Francais DOphtalmologie</i> , <b>2015</b> , 38, 573-9	0.8	1
384	Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: TREX-AMD 1-Year Results. <b>2015</b> , 122, 2514-22		177
383	Factors affecting visual acuity after one year of follow up after repeated intravitreal ranibizumab for macular degeneration. <b>2015</b> , 29, 187-91		2
382	Response-based individualized medicine for neovascular age-related macular degeneration. <b>2015</b> , 10, 105-112		2
381	Induction with intravitreal bevacizumab every two weeks in the management of neovascular age-related macular degeneration. <i>American Journal of Ophthalmology</i> , <b>2015</b> , 159, 131-7	4.9	17
380	Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen. <i>American Journal of Ophthalmology</i> , <b>2015</b> , 159, 3-8.e1	4.9	87
379	Visual acuity at presentation in the second eye versus first eye in patients with exudative age-related macular degeneration. <i>European Journal of Ophthalmology</i> , <b>2016</b> , 26, 44-7	1.9	6
378	Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes. <i>Clinical Ophthalmology</i> , <b>2016</b> , 10, 313-9	2.5	11
377	Twelve-month outcomes in patients with retinal vein occlusion treated with low-frequency intravitreal ranibizumab. <i>Clinical Ophthalmology</i> , <b>2016</b> , 10, 1161-5	2.5	13
376	Intravitreal Anti-Vascular Endothelial Growth Factor Therapy and Retinal Nerve Fiber Layer Loss in Eyes With Age-Related Macular Degeneration: A Meta-Analysis. <b>2016</b> , 57, 1798-806		30
375	Macular morphology and response to ranibizumab treatment in patients with wet age-related macular degeneration. <i>Clinical Ophthalmology</i> , <b>2016</b> , 10, 1117-22	2.5	12

374	Optical Coherence Tomography and the Development of Antiangiogenic Therapies in Neovascular Age-Related Macular Degeneration. <b>2016</b> , 57, OCT14-26		42
373	Treatment of neovascular age-related macular degeneration with anti-VEGF agents: retrospective analysis of 5-year outcomes. <i>Clinical Ophthalmology</i> , <b>2016</b> , 10, 541-6	2.5	13
372	Effect of Fluid Status at Week 12 on Visual and Anatomic Outcomes at Week 52 in the VIEW 1 and 2 Trials. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , <b>2016</b> , 47, 238-44	1.4	6
371	INTRAVITREAL RANIBIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN ANGIOID STREAKS: Four-Year Follow-up. <i>Retina</i> , <b>2016</b> , 36, 483-91	3.6	19
370	INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION: 5-Year Results of The Pan-American Collaborative Retina Study Group. <i>Retina</i> , <b>2016</b> , 36, 859-67	3.6	39
369	UNTREATED OBSTRUCTIVE SLEEP APNEA HINDERS RESPONSE TO BEVACIZUMAB IN AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , <b>2016</b> , 36, 791-7	3.6	22
368	IMPLICATION OF RECURRENT OR RETAINED FLUID ON OPTICAL COHERENCE TOMOGRAPHY FOR VISUAL ACUITY DURING ACTIVE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH A TREAT AND EXTEND PROTOCOL. <i>Retina</i> , <b>2016</b> , 36, 1331-9	3.6	36
367	Systemic safety of intravitreal anti-vascular endothelial growth factor agents in age-related macular degeneration. <b>2016</b> , 27, 224-43		9
366	Extended release anti-VEGF systems: a strategy whose time has come? Or already gone?. <b>2016</b> , 11, 167-169		
365	UK Neovascular Age-Related Macular Degeneration Database. Report 6: time to retreatment after a pause in therapy. Outcomes from 92 976 intravitreal ranibizumab injections. <b>2016</b> , 100, 1617-1622		13
364	Outcomes of intravitreal anti-VEGF therapy in eyes with both neovascular age-related macular degeneration and diabetic retinopathy. <b>2016</b> , 100, 1611-1616		5
363	Changing from a pro re nata treatment regimen to a treat and extend regimen with ranibizumab in neovascular age-related macular degeneration. <b>2016</b> , 100, 1341-5		31
362	Outcomes when Switching from a pro re nata Regimen to a Treat and Extend Regimen Using Aflibercept in Neovascular Age-Related Macular Degeneration. <b>2016</b> , 236, 201-206		13
361	CLINICAL TRIAL ENDPOINTS FOR OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , <b>2016</b> , 36 Suppl 1, S83-S92	3.6	32
360	Response of Pigment Epithelial Detachment to Anti-Vascular Endothelial Growth Factor Treatment in Age-Related Macular Degeneration. <i>American Journal of Ophthalmology</i> , <b>2016</b> , 166, 112-119	4.9	39
359	Efficacy of vitrectomy and inner limiting membrane peeling in age-related macular degeneration resistant to anti-vascular endothelial growth factor therapy, with vitreomacular traction or epiretinal membrane. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2016</b> , 254, 1731-6	3.8	8
358	Anti-vascular Endothelial Growth Factor (VEGF) Treatment in Neovascular Age-Related Macular Degeneration: Outcomes and Outcome Predictors. <b>2016</b> , 31-65		
357	Method development to quantify Bv8 expression in circulating CD11b+ cells in patients with neovascular age-related macular degeneration (nvAMD) exhibiting Anti-VEGF refractoriness. <b>2016</b> , 148, 45-51		4



356	Anti-angiogenic effect of ALS-L1023, an extract of <i>Melissa officinalis</i> L., on experimental choroidal neovascularization in mice. <b>2016</b> , 44, 43-51		
355	Aflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option. <i>Eye</i> , <b>2016</b> , 30, 1531-1541	4.4	9
354	Ranibizumab Treatment for Pigment Epithelial Detachment Secondary to Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of the HARBOR Study. <b>2016</b> , 123, 2213-24		29
353	Real world evidence of use of anti-VEGF therapy in Denmark. <b>2016</b> , 32, 1943-1950		19
352	Phase 2a Randomized Clinical Trial: Safety and Post Hoc Analysis of Subretinal rAAV.sFLT-1 for Wet Age-related Macular Degeneration. <b>2016</b> , 14, 168-175		97
351	Optical Coherence Tomography Angiography of Mixed Neovascularizations in Age-Related Macular Degeneration. <b>2016</b> , 56, 62-70		8
350	[Ranibizumab and exudative age-related macular degeneration: 5-year multicentric functional and anatomical results in real-life practice]. <i>Journal Francais DsOphtalmologie</i> , <b>2016</b> , 39, 668-674	0.8	10
349	Anti-Vascular Endothelial Growth Factor Agents in the Treatment of Retinal Disease: From Bench to Bedside. <b>2016</b> , 123, S78-S88		73
348	TREATMENT OUTCOMES FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION PATIENTS WITH INITIAL VISION BETTER THAN 20/40 USING A TREAT-AND-EXTEND REGIMEN. <i>Retina</i> , <b>2016</b> , 36, 875-80	3.6	10
347	Detection of aqueous VEGF concentrations before and after intravitreal injection of anti-VEGF antibody using low-volume sampling paper-based ELISA. <b>2016</b> , 6, 34631		30
346	Treatment schedules for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration. <b>2016</b> ,		4
345	LONG-TERM OUTCOMES OF INTRAVITREAL BEVACIZUMAB THERAPY FOR SUBRETINAL NEOVASCULARIZATION SECONDARY TO IDIOPATHIC MACULAR TELANGIECTASIA TYPE 2. <i>Retina</i> , <b>2016</b> , 36, 2150-2157	3.6	13
344	The concept of virtual clinics in monitoring patients with age-related macular degeneration. <i>Acta Ophthalmologica</i> , <b>2016</b> , 94, e353-5	3.7	21
343	Prevalence of outer retinal tubulation in eyes with choroidal neovascularization. <i>International Journal of Retina and Vitreous</i> , <b>2016</b> , 2, 6	2.9	8
342	AFLIBERCEPT FOR POLYPOIDAL CHOROIDAL VASCULOPATHY: As Needed Versus Fixed Interval Dosing. <i>Retina</i> , <b>2016</b> , 36, 1527-34	3.6	24
341	Comparison of Time to Retreatment and Visual Function Between Ranibizumab and Aflibercept in Age-Related Macular Degeneration. <i>American Journal of Ophthalmology</i> , <b>2016</b> , 169, 95-103	4.9	23
340	Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration (MERLOT): A Phase 3 Randomized Controlled Trial. <b>2016</b> , 123, 1287-96		10
339	Gas-mediated vitreomacular adhesion release with intravitreal ranibizumab injections for exudative age-related macular degeneration. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2016</b> , 254, 1681-92	3.8	1

338	Comparability of retinal thickness measurements using different scanning protocols on spectral-domain optical coherence tomography. <i>International Ophthalmology</i> , <b>2016</b> , 36, 791-797	2.2	1
337	Label propagation and higher-order constraint-based segmentation of fluid-associated regions in retinal SD-OCT images. <b>2016</b> , 358-359, 92-111		32
336	Defining a Minimum Set of Standardized Patient-centered Outcome Measures for Macular Degeneration. <i>American Journal of Ophthalmology</i> , <b>2016</b> , 168, 1-12	4.9	73
335	The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration—a phase IV randomised clinical trial with ranibizumab: the FLUID study. <b>2016</b> , 16, 31		54
334	Two-year results of combined intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation. <b>2016</b> , 60, 42-50		10
333	Ranibizumab for the treatment of wet AMD: a summary of real-world studies. <i>Eye</i> , <b>2016</b> , 30, 270-86	4.4	73
332	Inhibition of development of laser-induced choroidal neovascularization with suppression of infiltration of macrophages in Smad3-null mice. <b>2016</b> , 96, 641-51		14
331	A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration. <b>2016</b> , 100, 914-917		74
330	Retinal Pigment Epithelial Atrophy in Neovascular Age-Related Macular Degeneration After Ranibizumab Treatment. <i>American Journal of Ophthalmology</i> , <b>2016</b> , 161, 94-103.e1	4.9	32
329	Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration According to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol: Two-Year Results. <b>2016</b> , 123, 51-9		108
328	Radial versus raster spectral-domain optical coherence tomography scan patterns for detection of macular fluid in neovascular age-related macular degeneration. <b>2016</b> , 100, 491-4		7
327	Association of Apolipoprotein E Polymorphism with Intravitreal Ranibizumab Treatment Outcomes in Age-Related Macular Degeneration. <b>2016</b> , 41, 862-6		6
326	A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. <b>2016</b> , 50, 1-24		177
325	Long-term visual outcome and prognostic factors of Intravitreal anti-vascular endothelial growth factor treatment for retinal angiomatous proliferation. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2016</b> , 254, 23-30	3.8	21
324	Alternating Bi-Weekly Intravitreal Ranibizumab and Bevacizumab for Refractory Neovascular Age-Related Macular Degeneration with Pigment Epithelial Detachment. <b>2017</b> , 32, 309-315		5
323	Treat and Extend versus Pro Re Nata regimens of ranibizumab in neovascular age-related macular degeneration: a comparative 12 Month study. <i>Acta Ophthalmologica</i> , <b>2017</b> , 95, e67-e72	3.7	44
322	Short-term effects of intravitreal ranibizumab and bevacizumab administration on 24-h ambulatory blood pressure monitoring recordings in normotensive patients with age-related macular degeneration. <i>Eye</i> , <b>2017</b> , 31, 677-683	4.4	7
321	Identification and clinical role of choroidal neovascularization characteristics based on optical coherence tomography angiography. <i>Acta Ophthalmologica</i> , <b>2017</b> , 95, 414-420	3.7	51

320	Randomized Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: 2-Year Results of the TREX-AMD Study. <b>2017</b> , 1, 314-321		56
319	One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular degeneration. <i>Eye</i> , <b>2017</b> , 31, 878-883	4.4	27
318	Choroidal thickness and visual prognosis in type 1 lesion due to neovascular age-related macular degeneration. <i>European Journal of Ophthalmology</i> , <b>2017</b> , 27, 196-200	1.9	4
317	Bilateral Neovascular Age-Related Macular Degeneration: Comparisons between First and Second Eyes. <b>2017</b> , 238, 23-30		7
316	TREAT-AND-EXTEND REGIMEN USING RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY: One-Year Results. <i>Retina</i> , <b>2017</b> , 37, 561-567	3.6	13
315	UK AMD/DR EMR REPORT IX: comparative effectiveness of predominantly as needed (PRN) ranibizumab versus continuous aflibercept in UK clinical practice. <b>2017</b> , 101, 1683-1688		30
314	A systematic review to assess the 'treat-and-extend' dosing regimen for neovascular age-related macular degeneration using ranibizumab. <i>Eye</i> , <b>2017</b> , 31, 1337-1344	4.4	40
313	A Systematic Review of the Treat and Extend Treatment Regimen with Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration. <b>2017</b> , 6, 79-92		33
312	ROLE OF ADDITIONAL DEXAMETHASONE FOR THE MANAGEMENT OF PERSISTENT OR RECURRENT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION UNDER RANIBIZUMAB TREATMENT. <i>Retina</i> , <b>2017</b> , 37, 962-970	3.6	15
311	Effect of Epiretinal Membranes on Antivascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration. <i>Journal of Ocular Pharmacology and Therapeutics</i> , <b>2017</b> , 33, 452-458	2.6	7
310	Ranibizumab for choroidal neovascularization secondary to pseudoxanthoma elasticum: 4-year results from the PIXEL study in France. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2017</b> , 255, 1651-1660	3.8	8
309	Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2017</b> , 255, 1259-1273	3.8	71
308	Aflibercept in age-related macular degeneration: evaluating its role as a primary therapeutic option. <i>Eye</i> , <b>2017</b> , 31, 1523-1536	4.4	16
307	INTRAVITREAL AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH LIMITED RESPONSE TO RANIBIZUMAB: A Treat-and-Extend Trial. <i>Retina</i> , <b>2017</b> , 37, 1185-1192	3.6	8
306	RECURRENCE OF CHOROIDAL NEOVASCULARIZATION LESION ACTIVITY AFTER AFLIBERCEPT TREATMENT FOR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , <b>2017</b> , 37, 2062-2068	3.6	11
305	[Rational treatment of exudative AMD: Request for therapeutic uniform practice. The "know & treat"]. <i>Journal Francais DsOphtalmologie</i> , <b>2017</b> , 40, 165-168	0.8	0
304	[Individualized management of patients with exudative AMD, IOI protocol: Injection-observational-individualization]. <i>Journal Francais DsOphtalmologie</i> , <b>2017</b> , 40, 169-176	0.8	2
303	One-Year Outcomes of a Treat-and-Extend Regimen of Aflibercept for Exudative Age-Related Macular Degeneration. <b>2017</b> , 237, 139-144		19

302	One-Year Outcomes of 1 + pro re nata versus 3 + pro re nata Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration. <b>2017</b> , 237, 105-110		9
301	Association of Repeated Intravitreal Bevacizumab Injections With Risk for Glaucoma Surgery. <b>2017</b> , 135, 363-368		30
300	Ranibizumab for vascularized pigment epithelial detachment: 1-year anatomic and functional results. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2017</b> , 255, 743-751	3.8	8
299	[A "fast track" to improve management of neovascular age related macular degeneration]. <i>Journal Francais DOphtalmologie</i> , <b>2017</b> , 40, 642-647	0.8	3
298	[Treatment of choroidal neovascularization secondary to angioid streaks with bevacizumab and response: Experience of the ophthalmology department of Hassan II university hospital]. <i>Journal Francais DOphtalmologie</i> , <b>2017</b> , 40, 731-737	0.8	
297	[Management of wet AMD in France in 2015]. <i>Journal Francais DOphtalmologie</i> , <b>2017</b> , 40, 723-730	0.8	2
296	SAVE-AMD: Safety of VEGF Inhibitors in Age-Related Macular Degeneration. <b>2017</b> , 238, 205-216		8
295	Different Clinical Courses on Long-Term Follow-Up of Age-Related Macular Degeneration Patients Treated with Intravitreal Anti-Vascular Endothelial Growth Factor Injections. <b>2017</b> , 238, 217-225		7
294	High-density lipoprotein mutant eye drops for the treatment of posterior eye diseases. <b>2017</b> , 266, 301-309		23
293	Two-Year Outcomes of a Treat-and-Extend Regimen Using Intravitreal Aflibercept Injections for Typical Age-Related Macular Degeneration. <b>2017</b> , 238, 236-242		13
292	Long-Term Outcomes of Two Different Initial Dosing Regimens of Intravitreal Ranibizumab Used to Treat Myopic Choroidal Neovascularization. <b>2017</b> , 238, 196-204		4
291	Treatment for neovascular age-related macular degeneration in Sweden: outcomes at seven years in the Swedish Macula Register. <i>Acta Ophthalmologica</i> , <b>2017</b> , 95, 787-795	3.7	16
290	An 8-year follow-up of anti-vascular endothelial growth factor treatment with a treat-and-extend modality for neovascular age-related macular degeneration. <i>Acta Ophthalmologica</i> , <b>2017</b> , 95, 796-802	3.7	48
289	Principles of pharmacology in the eye. <b>2017</b> , 174, 4205-4223		79
288	ARMS2 A69S polymorphism is associated with the number of ranibizumab injections needed for exudative age-related macular degeneration in a pro re nata regimen during 4 years of follow-up. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2017</b> , 255, 2091-2098	3.8	8
287	Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with Aflibercept. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2017</b> , 255, 2127-2134	3.8	19
286	[Eye Drops Instead of Intravitreal Injections? The Dream of Treating Macular Diseases by Topically Administered Drugs]. <b>2017</b> , 234, 1088-1093		1
285	Hot Topics in Pharmacotherapy for Neovascular Age-Related Macular Degeneration. <b>2017</b> , 23, 535-541		5

284	Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2017</b> , 255, 1891-1897	3.8	40
283	24-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life setting. <b>2017</b> , 17, 58		17
282	Current advances in the treatment of neovascular age-related macular degeneration. <b>2017</b> , 14, 273-282		55
281	Evaluation of outer retinal tubulations in eyes switched from intravitreal ranibizumab to aflibercept for treatment of exudative age-related macular degeneration. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2017</b> , 255, 61-67	3.8	4
280	Recommended Guidelines for Use of Intravitreal Aflibercept With a Treat-and-Extend Regimen for the Management of Neovascular Age-Related Macular Degeneration in the Asia-Pacific Region: Report From a Consensus Panel. <b>2017</b> , 6, 296-302		12
279	The ARMOUR Study: Anti-VEGF in Neovascular AMD--Our Understanding in a Real-World Indian Setting. <b>2017</b> , 6, 488-492		3
278	Recent developments in age-related macular degeneration: a review. <b>2017</b> , 12, 1313-1330		168
277	The ecosystem that powered the translation of OCT from fundamental research to clinical and commercial impact [Invited]. <b>2017</b> , 8, 1638-1664		63
276	Response of eyes with age-related macular degeneration to anti-VEGF drugs and implications for therapy planning. <i>Clinical Ophthalmology</i> , <b>2017</b> , 11, 809-816	2.5	9
275	Intrinsically Photosensitive Retinal Ganglion Cell Function, Sleep Efficiency and Depression in Advanced Age-Related Macular Degeneration. <b>2017</b> , 58, 990-996		29
274	Assessment of Corneal Sensation, Innervation and Retinal Nerve Fiber Layer in Patients Treated with Multiple Intravitreal Ranibizumab Injections. <i>PLoS ONE</i> , <b>2017</b> , 12, e0170271	3.7	3
273	Advanced quantitative analysis of the sub-retinal pigment epithelial space in recurrent neovascular age-related macular degeneration. <i>PLoS ONE</i> , <b>2017</b> , 12, e0186955	3.7	4
272	Predictive models of long-term anatomic outcome in age-related macular degeneration treated with as-needed Ranibizumab. <b>2017</b> , 17, 147		8
271	Treatment Burden in Neovascular AMD: Visual Acuity Outcomes are Associated With Anti-VEGF Injection Frequency. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , <b>2017</b> , 48, 780-784	1.4	20
270	Efficacy and safety of ranibizumab for wet age-related macular degeneration in Chinese patients. <i>International Journal of Ophthalmology</i> , <b>2017</b> , 10, 91-97	1.4	3
269	Fourteen Anti-vascular Endothelial Growth Factor Injections for Age-related Macular Degeneration: Ending Period and Clinical Outcome. <b>2017</b> , 58, 1042		2
268	New molecular targets for the treatment of neovascular age-related macular degeneration. <b>2017</b> , 1,		
267	Combination verteporfin photodynamic therapy ranibizumab-dexamethasone in choroidal neovascularization due to age-related macular degeneration: results of a phase II randomized trial. <i>Clinical Ophthalmology</i> , <b>2017</b> , 11, 223-231	2.5	9

266	Testing the clinical value of multifocal electroretinography and microperimetry and the effects of intravitreal therapy with ranibizumab on macular function in the course of wet age-related macular degeneration: a 1-year prospective study. <i>Clinical Ophthalmology</i> , <b>2017</b> , 11, 621-629	2.5	5
265	Comparison of Neovascular Lesion Area Measurements From Different Swept-Source OCT Angiographic Scan Patterns in Age-Related Macular Degeneration. <b>2017</b> , 58, 5098-5104		16
264	Long-term Results of Reduced-fluence Photodynamic Therapy Combined with Intravitreal Anti-Vascular Endothelial Growth Factor for Polypoidal Choroidal Vasculopathy. <b>2017</b> , 58, 646		
263	Estimating Medicare and Patient Savings From the Use of Bevacizumab for the Treatment of Exudative Age-related Macular Degeneration. <i>American Journal of Ophthalmology</i> , <b>2018</b> , 191, 135-139	4.9	21
262	Comparison of macular parameters after femtosecond laser-assisted and conventional cataract surgery in age-related macular degeneration. <b>2018</b> , 44, 23-27		3
261	Efficacy of treat-and-extend regimen with aflibercept for pachychoroid neovascularopathy and Type 1 neovascular age-related macular degeneration. <b>2018</b> , 62, 144-150		46
260	Consistent Long-Term Therapy of Neovascular Age-Related Macular Degeneration Managed by 50 or More Anti-VEGF Injections Using a Treat-Extend-Stop Protocol. <b>2018</b> , 125, 1047-1053		39
259	Development of Age-Related Macular Degeneration (AMD) in the Fellow Eye of Patients with AMD Treated by Treat-and-Extend Intravitreal Therapy with Aflibercept. <b>2018</b> , 239, 121-127		2
258	Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors. <b>2018</b> , 65, 127-146		128
257	Long-Term Outcomes in Patients with Neovascular Age-Related Macular Degeneration Who Maintain Dry Macula after Three Monthly Ranibizumab Injections. <b>2018</b> , 33, 371-376		4
256	Retreatment of Exudative Age-Related Macular Degeneration after Loading 3-Monthly Intravitreal Ranibizumab. <b>2018</b> , 239, 52-59		7
255	Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration: Results with Ranibizumab from the TREND Study. <b>2018</b> , 125, 57-65		145
254	Spending Money to Save Money on Patient Care-The Development of Optical Coherence Tomography. <i>American Journal of Ophthalmology</i> , <b>2018</b> , 185, 8-9	4.9	
253	Morphologic Criteria of Lesion Activity in Neovascular Age-Related Macular Degeneration: A Consensus Article. <i>Journal of Ocular Pharmacology and Therapeutics</i> , <b>2018</b> , 34, 298-308	2.6	5
252	Age-related macular degeneration: using morphological predictors to modify current treatment protocols. <i>Acta Ophthalmologica</i> , <b>2018</b> , 96, 120-133	3.7	34
251	Neovascular age-related macular degeneration management in the third year: final results from the TREX-AMD randomised trial. <b>2018</b> , 102, 460-464		31
250	Real-World Outcomes of Anti-VEGF Treatment for Neovascular Age-Related Macular Degeneration in Turkey: A Multicenter Retrospective Study, Bosphorus Retina Study Group Report No: 1. <b>2018</b> , 48, 232-237		6
249	Novel devices for studying acute and chronic mechanical stress in retinal pigment epithelial cells. <b>2018</b> , 18, 3413-3424		11

248	Real-life experience of ranibizumab therapy for neovascular age-related macular degeneration from Turkey. <i>International Journal of Ophthalmology</i> , <b>2018</b> , 11, 267-273	1.4	2
247	A simulation tool for better management of retinal services. <b>2018</b> , 18, 759		6
246	Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group. <i>Clinical Ophthalmology</i> , <b>2018</b> , 12, 1731-1740	2.5	16
245	[Update from France Macula Federation: Treatment of Wet AMD]. <i>Journal Francais DsOphtalmologie</i> , <b>2018</b> , 41, 862-867	0.8	3
244	Drug Delivery to Posterior Segment of the Eye: Conventional Delivery Strategies, Their Barriers, and Restrictions. <b>2018</b> , 51-67		5
243	Ranibizumab treatment history as predictor of the switch-response to aflibercept: evidence for drug tolerance. <i>Clinical Ophthalmology</i> , <b>2018</b> , 12, 593-600	2.5	7
242	Treatment Efficacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life Setting. <b>2018</b> , 2018, 4610129		21
241	Swept-Source OCT Angiography Identifies Choroidal Neovascularization Arising From a Choroidal Nevus. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , <b>2018</b> , 49, 360-363	1.4	4
240	Recent Innovations in Drug Delivery for Retinal Diseases. <b>2018</b> , 3, 155-183		1
239	Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen. <b>2018</b> , 18, 144		5
238	Morphological Predictive Features on Spectral-Domain Optical Coherence Tomography for Visual Outcomes in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab. <b>2018</b> , 2018, 7438083		2
237	Neovascular Age-Related Macular Degeneration: A Visual Acuity Model of Natural Disease Progression and Ranibizumab Treatment Effect. <b>2018</b> , 7, 660-669		6
236	Retinal pigmental epithelium elevation and external limiting membrane interruption in myopic choroidal neovascularization: correlation with activity. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2018</b> , 256, 1831-1837	3.8	7
235	Real-World Results of Aflibercept versus Ranibizumab for the Treatment of Exudative AMD Using a Fixed Regimen. <b>2018</b> , 2018, 9276580		6
234	Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab. <b>2018</b> , 18, 20		1
233	14 Age-Related Macular Degeneration. <b>2018</b> ,		
232	Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration. <b>2018</b> , 24, S3-S15		59
231	The Treat-and-Extend Injection Regimen Versus Alternate Dosing Strategies in Age-related Macular Degeneration: A Systematic Review and Meta-analysis. <i>American Journal of Ophthalmology</i> , <b>2018</b> , 192, 184-197	4.9	42

230	Characteristics of patients with neovascular age-related macular degeneration who are non-responders to intravitreal aflibercept. <b>2018</b> ,			11
229	Long-term results of photodynamic therapy or ranibizumab for polypoidal choroidal vasculopathy in LAPTOP study. <b>2019</b> , 103, 844-848			13
228	[Clinical parameters of patients with neovascular age-related macular degeneration : Longterm treatment results of an outpatient clinic]. <b>2019</b> , 116, 430-434			
227	Spectral Domain Optical Coherence Tomography Allows the Unification of Clinical Decision Making for the Evaluation of Choroidal Neovascularization Activity. <b>2019</b> , 241, 32-37			3
226	Time trends, disease patterns and gender imbalance in the top 100 most cited articles in ophthalmology. <b>2019</b> , 103, 18-25			11
225	Segmentation of Symptomatic Exudate-Associated Derangements in 3D OCT Images. <b>2019</b> , 345-365			
224	Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2019</b> , 257, 1889-1895	3.8		39
223	Retinal Optical Coherence Tomography Image Analysis. <b>2019</b> ,			2
222	One-Year Outcomes of 1 Dose versus 3 Loading Doses Followed by Pro Re Nata Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration: The ARTIS Trial. <b>2019</b> , 2019, 7530458			5
221	Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. <b>2019</b> , 3, CD005139			67
220	Anti-VEGF intervention in neovascular AMD: benefits and risks restated as natural frequencies. <i>BMJ Open Ophthalmology</i> , <b>2019</b> , 4, e000257	3.2		1
219	Clinical efficacy and safety of ranibizumab in the treatment of wet age-related macular degeneration. <b>2019</b> , 19, 735-751			13
218	Long-term effect of intravitreal ranibizumab therapy on retinal nerve fiber layer in eyes with exudative age-related macular degeneration. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2019</b> , 257, 1459-1466	3.8		7
217	OPTICAL COHERENCE TOMOGRAPHY, FLUORESCEIN ANGIOGRAPHY, AND DIAGNOSIS OF CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , <b>2019</b> , 39, 1664-1671	3.6		13
216	Lessons Learned From Avastin and OCT-The Great, the Good, the Bad, and the Ugly: The LXXV Edward Jackson Memorial Lecture. <i>American Journal of Ophthalmology</i> , <b>2019</b> , 204, 26-45	4.9		6
215	Feasibility of support vector machine learning in age-related macular degeneration using small sample yielding sparse optical coherence tomography data. <i>Acta Ophthalmologica</i> , <b>2019</b> , 97, e719-e728	3.7		5
214	The use of real-world evidence for evaluating anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration. <b>2019</b> , 64, 707-719			18
213	One-year outcomes of intravitreal conbercept combined rescue therapy for polypoidal choroidal vasculopathy in a Chinese population: a real-life clinical data. <i>International Journal of Ophthalmology</i> , <b>2019</b> , 12, 51-57	1.4		4



212	Genetic biomarkers in the VEGF pathway predicting response to anti-VEGF therapy in age-related macular degeneration. <i>BMJ Open Ophthalmology</i> , <b>2019</b> , 4, e000273	3.2	3
211	Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review. <i>BMJ Open Ophthalmology</i> , <b>2019</b> , 4, e000398	3.2	38
210	Predictors of neovascular activity during neovascular age-related macular degeneration treatment based on optical coherence tomography angiography. <b>2019</b> , 9, 19240		10
209	[Impact of mydriatic eyedrops on distance visual acuity in patients with exudative age-related macular degeneration]. <i>Journal Francais DsOphthalmologie</i> , <b>2019</b> , 42, 880-893	0.8	
208	Optical coherence tomography angiography in exudative age-related macular degeneration: a predictive model for treatment decisions. <b>2019</b> , 103, 1342-1346		27
207	Correlation between macular structure and function in patients with age-related macular degeneration treated with intravitreal ranibizumab: 12-month-results. <b>2019</b> , 63, 90-99		2
206	[Pro re nata anti-VEGF treatment results for neovascular age-related macular degeneration in routine clinical treatment: comparison of single with triple injections]. <b>2019</b> , 116, 441-446		1
205	COMPARISON AMONG DIFFERENT DIAGNOSTIC METHODS IN THE STUDY OF TYPE AND ACTIVITY OF CHOROIDAL NEOVASCULAR MEMBRANES IN AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , <b>2019</b> , 39, 281-287	3.6	6
204	SHORT-TERM EFFICACY OF CONBERCEPT AND RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY. <i>Retina</i> , <b>2019</b> , 39, 889-895	3.6	12
203	INCIDENCE AND LONG-TERM VISUAL ACUITY OUTCOMES OF RETINAL PIGMENT EPITHELIUM TEARS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , <b>2019</b> , 39, 664-669	3.6	6
202	Abicipar pegol: the non-monoclonal antibody anti-VEGF. <i>Eye</i> , <b>2020</b> , 34, 797-801	4.4	8
201	Are Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular Degeneration?. <b>2020</b> , 4, 141-147		5
200	Assessment of Exudative Activity of Choroidal Neovascularization in Age-Related Macular Degeneration by OCT Angiography. <b>2020</b> , 243, 120-128		11
199	A Review of Macular Atrophy of the Retinal Pigment Epithelium in Patients with Neovascular Age-Related Macular Degeneration: What is the Link? Part II. <b>2020</b> , 9, 35-75		4
198	Comparison of Automated versus Manually Modified OCT Angiography En Face Slabs for Detection of Choroidal Neovascularization. <b>2020</b> , 4, 471-480		4
197	Objective Evaluation of Proliferative Diabetic Retinopathy Using OCT. <b>2020</b> , 4, 164-174		16
196	RANIBIZUMAB TREATMENT IN TREATMENT-NAIVE NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Results From LUMINOUS, a Global Real-World Study. <i>Retina</i> , <b>2020</b> , 40, 1673-1685	3.6	35
195	Real-World Treatment Outcomes of Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in Asians. <b>2020</b> , 4, 403-414		12

194	Ten-year survival trends of neovascular age-related macular degeneration at first presentation. <b>2021</b> , 105, 1688-1695		5
193	Three-year outcome of aflibercept treatment for Japanese patients with neovascular age-related macular degeneration. <b>2020</b> , 20, 276		5
192	Correlation of Baseline Visual Acuity with Outcomes of Treatment with Anti-VEGF in Neovascular Age-Related Macular Degeneration. <i>Clinical Ophthalmology</i> , <b>2020</b> , 14, 1565-1572	2.5	5
191	Association between Polygenic Risk Score and One-Year Outcomes Following As-Needed Aflibercept Therapy for Exudative Age-Related Macular Degeneration. <b>2020</b> , 13,		5
190	Long-Term Visual Outcomes for a Treat-and-Extend Antivascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration: Up to Seven-Year Follow-Up. <b>2020</b> , 2020, 3207614		3
189	Clinical-Decision Criteria to Identify Recurrent Diabetic Macular Edema Patients Suitable for Fluocinolone Acetonide Implant Therapy (ILUVIEN) and Follow-Up Considerations/Recommendations. <i>Clinical Ophthalmology</i> , <b>2020</b> , 14, 2091-2107	2.5	2
188	A Trinity regimen with aflibercept for treatment-naïve neovascular age-related macular degeneration: 2-year outcomes. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2020</b> , 258, 1663-1670	3.8	1
187	Visual benefit versus visual gain: what is the effect of baseline covariants in the treatment arm relative to the control arm? A pooled analysis of ANCHOR and MARINA. <b>2020</b> , 104, 672-677		6
186	Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration. <b>2020</b> , 5, CD012208		21
185	Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records. <b>2020</b> , 127, 1179-1188		11
184	Clinical outcomes of 1 + PRN and 3 + Q3M regimens of intravitreal conbercept injection for exudative age-related macular degeneration. <b>2020</b> , 10, 8010		1
183	Bimonthly, treat-and-extend and as-needed ranibizumab in naïve neovascular age-related macular degeneration patients: 12-month outcomes of a randomized study. <i>Acta Ophthalmologica</i> , <b>2020</b> , 98, e820-e829	3.7	7
182	Quantitative Optical Coherence Tomography Angiography Biomarkers in a Treat-and-Extend Dosing Regimen in Neovascular Age-Related Macular Degeneration. <b>2020</b> , 9, 18		3
181	Patient Preferences for Anti-Vascular Endothelial Growth Factor Treatment for Wet Age-Related Macular Degeneration in Japan: A Discrete Choice Experiment. <b>2020</b> , 14, 553-567		7
180	Iatrogenic ophthalmic artery occlusion and retinal artery occlusion. <b>2020</b> , 100848		9
179	Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUS Study. <i>Clinical Ophthalmology</i> , <b>2020</b> , 14, 1473-1481	2.5	0
178	Impact of intravitreal aflibercept dosing regimens in treatment-naïve patients with neovascular age-related macular degeneration in routine clinical practice in France: results from the RAINBOW study. <i>BMJ Open Ophthalmology</i> , <b>2020</b> , 5, e000377	3.2	1
177	Methodological Challenges of Deep Learning in Optical Coherence Tomography for Retinal Diseases: A Review. <b>2020</b> , 9, 11		28

176	Macular function following intravitreal ranibizumab for macular edema associated with branch retinal vein occlusion: 12-month results. <b>2020</b> , 141, 127-136		1
175	The relationship between pigment epithelial detachment and visual outcome in neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. <i>Eye</i> , <b>2020</b> , 34, 2257-2263	4.4	4
174	Phase I/II randomized study of proton beam with anti-VEGF for exudative age-related macular degeneration: long-term results. <i>Eye</i> , <b>2020</b> , 34, 2271-2279	4.4	2
173	Seven-Year Visual and Anatomical Outcomes of Intravitreal Vascular Endothelial Growth Factor Inhibition for Neovascular Age-Related Macular Degeneration. <b>2020</b> , 2020, 8345850		2
172	A systematic approach to evaluate practice-based process- and outcome data applied to the treatment of neovascular age-related macular degeneration. <b>2020</b> , 20, 21		
171	OCT Angiography Features of Neovascularization as Predictive Factors for Frequent Recurrence in Age-Related Macular Degeneration. <i>American Journal of Ophthalmology</i> , <b>2020</b> , 213, 109-119	4.9	11
170	Unique optical coherence tomographic features in age-related macular degeneration. <b>2020</b> , 65, 451-457		8
169	Complications in Uveitis. <b>2020</b> ,		
168	Functional versus functional and anatomical criteria-guided ranibizumab treatment in patients with neovascular age-related macular degeneration - results from the randomized, phase IIIb OCTAVE study. <b>2020</b> , 20, 18		4
167	Genetic factors associated with response to as-needed aflibercept therapy for typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. <b>2020</b> , 10, 7188		7
166	Retinal neurodegeneration in patients with end-stage renal disease assessed by spectral-domain optical coherence tomography. <b>2020</b> , 10, 5255		3
165	Factors associated with extended remission in neovascular age-related macular degeneration on pro re nata treatment protocol. <b>2020</b> , 104, 58-63		5
164	Twenty-four-month outcomes of inflammatory choroidal neovascularisation treated with intravitreal anti-vascular endothelial growth factors: a comparison between two treatment regimens. <b>2020</b> , 104, 1052-1056		9
163	Intraocular Pharmacokinetics of 10-fold Intravitreal Ranibizumab Injection Dose in Rabbits. <b>2020</b> , 9, 7		5
162	Influence of pigment epithelial detachment on visual acuity in neovascular age-related macular degeneration. <b>2021</b> , 66, 68-97		7
161	One-year results of intravitreal conbercept in treatment-naïve subjects with polypoidal choroidal vasculopathy. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2021</b> , 259, 1455-1462	3.8	2
160	Quantitative Analysis of OCT for Neovascular Age-Related Macular Degeneration Using Deep Learning. <b>2021</b> , 128, 693-705		19
159	Long non-coding RNA PWRN2 regulates cytotoxicity in an in vitro model of age-related macular degeneration. <b>2021</b> , 535, 39-46		3

158	Pharmacotherapy of Age-Related Macular Degeneration. <b>2021</b> , 1-26		
157	Mingjing granule, a traditional Chinese medicine in the treatment of neovascular age-related macular degeneration: study protocol for a randomized controlled trial. <b>2021</b> , 22, 69		0
156	One-year comparison of anti-vascular endothelial growth factor and half-dose photodynamic therapies for pachychoroid neovascularopathy. <i>Eye</i> , <b>2021</b> , 35, 3367-3375	4.4	5
155	Optical Coherence Tomography Angiography Quality Across Three Multicenter Clinical Studies of Diabetic Retinopathy. <b>2021</b> , 10, 2		4
154	Five-Year Outcome of Aflibercept Monotherapy for Exudative Age-Related Macular Degeneration with Good Baseline Visual Acuity. <b>2021</b> , 10,		1
153	Importance of Anatomical Efficacy for Disease Control in Neovascular AMD: An Expert Opinion. <b>2021</b> , 10, 231-243		0
152	Comparing Effectiveness of Three Different Anti-VEGF Treatment Regimens for Neovascular Age-Related Macular Degeneration: Two Years' Real-World Clinical Outcomes. <i>Clinical Ophthalmology</i> , <b>2021</b> , 15, 1703-1713	2.5	2
151	Characterisation of macular neovascularisation in geographic atrophy. <b>2021</b> ,		0
150	PRN Treatment of Neovascular AMD with Cycles of Three Monthly Injections. <i>Journal of Ophthalmic and Vision Research</i> , <b>2021</b> , 16, 178-186	1.2	1
149	One year outcomes of treat and extend and pro re nata (PRN) treatment regimens with aflibercept for polypoidal choroidal vasculopathy. <i>European Journal of Ophthalmology</i> , <b>2021</b> , 31, 2868-2875	1.9	1
148	The role of future treatments in the management of neovascular age-related macular degeneration in Europe. <i>European Journal of Ophthalmology</i> , <b>2021</b> , 31, 2179-2188	1.9	
147	RETINAL FLUID AND THICKNESS AS MEASURES OF DISEASE ACTIVITY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , <b>2021</b> , 41, 1579-1586	3.6	2
146	Anti-VEGF-resistant subretinal fluid is associated with better vision and reduced risk of macular atrophy. <b>2021</b> ,		2
145	Prospective, Longitudinal Pilot Study. <b>2021</b> , 1, 100034		5
144	Treat and extend paradigm in management of neovascular age-related macular degeneration: current practice and future directions. <b>2021</b> , 16, 267-286		
143	Probabilistic Forecasting of Anti-VEGF Treatment Frequency in Neovascular Age-Related Macular Degeneration. <b>2021</b> , 10, 30		3
142	Real-Time Photographic- and Fluorescein Angiographic-Guided Management of Diabetic Retinopathy: Randomized PRIME Trial Outcomes. <i>American Journal of Ophthalmology</i> , <b>2021</b> , 226, 126-136	4.9	4
141	AI-based monitoring of retinal fluid in disease activity and under therapy. <b>2021</b> , 100972		5

140	Real-World Experience with Brolocizumab in Wet Age-Related Macular Degeneration: The REBA Study. <b>2021</b> , 10,		11
139	Neovascular age-related macular degeneration at treatment intervals of 14 weeks or greater. <b>2021</b> , 49, 570-578		1
138	Proportion and Reasons for Ineligibility to Re-register for Extended Health Insurance in Neovascular Age-related Macular Degeneration. <b>2021</b> , 62, 948-956		
137	Long-term outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. <b>2021</b> , 11, 14623		0
136	Analyses of the effects of persistent subretinal fluid on visual/anatomic outcomes according to the type of macular neovascularization during the relaxed treat-and-extend protocol in age-related macular degeneration patients. <b>2021</b> , 21, 294		0
135	Evolving Treatment Patterns and Outcomes of Neovascular Age-Related Macular Degeneration Over a Decade. <b>2021</b> , 5, e11-e22		2
134	Predictors of Visual Acuity After Treatment of Neovascular Age-Related Macular Degeneration - Current Perspectives. <i>Clinical Ophthalmology</i> , <b>2021</b> , 15, 3351-3367	2.5	0
133	Real Life Data of Treat and Extend Intravitreal Ranibizumab and Aflibercept Therapy in Wet Age-related Macular Degeneration Patients: 3-Year Results. <b>2021</b> , 35, 280-286		
132	Visual acuity outcomes of anti-VEGF treatment for neovascular age-related macular degeneration in clinical trials. <b>2021</b> , 65, 741-760		2
131	SINGLE INJECTION RESPONSE TO ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS IN PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION: Incidence and Characteristics. <i>Retina</i> , <b>2021</b> , 41, 1901-1910	3.6	3
130	Prechoroidal cleft thickness correlates with disease activity in neovascular age-related macular degeneration. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2021</b> , 1	3.8	
129	Morphological characteristics of eyes with neovascular age-related macular degeneration and good long-term visual outcomes after anti-VEGF therapy. <b>2021</b> ,		2
128	Deep learning based joint segmentation and characterization of multi-class retinal fluid lesions on OCT scans for clinical use in anti-VEGF therapy. <b>2021</b> , 136, 104727		14
127	Topical Triamcinolone Acetonide-Loaded Liposome Formulation Used as an Adjuvant to Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration. <b>2021</b> , 13,		1
126	Initial Pro Re Nata Brolocizumab for Exudative AMD: The PROBE Study. <b>2021</b> , 10,		2
125	Current Management of Age-Related Macular Degeneration. <b>2021</b> , 1256, 295-314		1
124	Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial. <b>2021</b> , 139, 68-76		16
123	Automated Deep Learning-based Multi-class Fluid Segmentation in Swept-Source Optical Coherence Tomography Images.		2

122	Progression of macular atrophy in patients undergoing anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration. <i>Acta Ophthalmologica</i> , <b>2021</b> , 99, e540-e546	3.7	5
121	Retinal pigment epithelial atrophy after anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy. <b>2020</b> , 104, 1443-1447		7
120	Recent developments in the treatment of age-related macular degeneration. <b>2014</b> , 124, 1430-8		118
119	VEGF regulates local inhibitory complement proteins in the eye and kidney. <b>2017</b> , 127, 199-214		82
118	Effectiveness of ranibizumab intravitreal injections for exudative age-related macular degeneration treatment: 12-month outcomes. <b>2011</b> , 17, CR485-90		6
117	Influence of ranibizumab treatment on the extracellular matrix in patients with neovascular age-related macular degeneration. <b>2014</b> , 20, 875-83		5
116	The Chronic Care for Wet Age Related Macular Degeneration (CHARMED) Study: A Randomized Controlled Trial. <i>PLoS ONE</i> , <b>2015</b> , 10, e0143085	3.7	6
115	[Anti-VEGF dosing regimen for neovascular age-related macular degeneration treatment]. <b>2018</b> , 134, 107-115		2
114	Dosing regimens of angiogenesis inhibitors in the treatment of neovascular age-related macular degeneration patients. <b>2019</b> , 12, 47-56		2
113	Ocular neovascular-related diseases: immunological mechanisms of development and the potential of anti-angiogenic therapy. <b>2016</b> , 9, 58-67		4
112	Fixed bimonthly aflibercept in naïve and switched neovascular age-related macular degeneration patients: one year outcomes. <i>International Journal of Ophthalmology</i> , <b>2016</b> , 9, 1156-62	1.4	6
111	Gene, Cell and Antibody-Based Therapies for the Treatment of Age-Related Macular Degeneration. <b>2020</b> , 14, 83-94		9
110	Anti-VEGF Treatment and Response in Age-related Macular Degeneration: Disease's Susceptibility, Pharmacogenetics and Pharmacokinetics. <b>2020</b> , 27, 549-569		6
109	Clinical risk factors for poor anatomic response to ranibizumab in neovascular age-related macular degeneration. <b>2014</b> , 8, 3-6		7
108	Incidence of Retinal Pigment Epithelial Tears and Associated Risk Factors After Treatment of Age-Related Macular Degeneration with Intravitreal Anti-VEGF Injections. <b>2014</b> , 8, 101-4		10
107	Anti-vascular Endothelial Growth Factor Outpatient Treatment Patterns in Patients with Exudative Age-related Macular Degeneration from a Japanese Hospital Claims Database. <b>2014</b> , 2, 41-52		4
106	Angiographic regression patterns after intravitreal ranibizumab injections for neovascular age-related macular degeneration. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , <b>2011</b> , 42, 498-508	1.4	11
105	Automated detection of the foveal center improves SD-OCT measurements of central retinal thickness. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , <b>2012</b> , 43, S32-7	1.4	11

104	Meta-analysis of infectious endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , <b>2014</b> , 45, 143-9	1.4	135
103	Ultrahigh-speed swept-source OCT angiography in exudative AMD. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , <b>2014</b> , 45, 496-505	1.4	171
102	Cost comparison of intravitreal aflibercept with bevacizumab and ranibizumab for the treatment of wet age-related macular degeneration. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , <b>2015</b> , 46, 62-6	1.4	14
101	Comparison of retinal thicknesses measured using swept-source and spectral-domain optical coherence tomography devices. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , <b>2015</b> , 46, 172-9	1.4	36
100	Improved repeatability of retinal thickness measurements using line-scan ophthalmoscope image-based retinal tracking. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , <b>2015</b> , 46, 310-4	1.4	6
99	Relationship Between Subretinal Hyperreflective Material Reflectivity and Volume in Patients With Neovascular Age-Related Macular Degeneration Following Anti-Vascular Endothelial Growth Factor Treatment. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , <b>2015</b> , 46, 523-30	1.4	27
98	Experience With Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , <b>2015</b> , 46, 542-9	1.4	5
97	36-Month Evaluation of Intravitreal Aflibercept Injection for Wet Age-Related Macular Degeneration in Patients Previously Treated With Ranibizumab or Bevacizumab. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , <b>2018</b> , 49, 179-185	1.4	1
96	Effects of multiple intravitreal anti-VEGF injections on retinal nerve fiber layer and intraocular pressure: a comparative clinical study. <i>International Journal of Ophthalmology</i> , <b>2013</b> , 6, 211-5	1.4	18
95	Combination of ranibizumab with photodynamic therapy vs ranibizumab monotherapy in the treatment of age-related macular degeneration: a systematic review and meta-analysis of randomized controlled trials. <i>International Journal of Ophthalmology</i> , <b>2014</b> , 7, 541-9	1.4	10
94	Morphological changes in spectral domain optical coherence tomography guided bevacizumab injections in wet age-related macular degeneration, 12-months results. <b>2014</b> , 62, 554-60		4
93	Long-term outcomes of combination photodynamic therapy with ranibizumab or bevacizumab for treatment of wet age-related macular degeneration. <b>2016</b> , 9, 87-92		3
92	Management of Neovascular Age-related Macular Degeneration: A Review on Landmark Randomized Controlled Trials. <b>2016</b> , 23, 27-37		19
91	Bilateral concomitant intravitreal anti-vascular endothelial growth factor injection: Experience in a Nigerian tertiary private eye care facility. <b>2016</b> , 19, 544-8		3
90	Intravitreal injections: A review of pharmacological agents and techniques. <b>2016</b> , 4, 51		8
89	Subgroups and Features of Poor Responders to Anti-Vascular Endothelial Growth Factor Treatment in Eyes with Neovascular Age-Related Macular Degeneration. <b>2020</b> , 50, 275-282		2
88	One-year results of aflibercept in vascularized pigment epithelium detachment due to neovascular AMD: a prospective study. <i>European Journal of Ophthalmology</i> , <b>2017</b> , 27, 74-79	1.9	6
87	Choroidal neovascularization secondary to pathological myopia. <b>2014</b> , 4, 35		1

- 86 The combination therapy of subtenon triamcinolone acetonide injection and intravitreal brolocizumab for brolocizumab-related intraocular inflammation. **2021**, 100, e27580 3
- 85 Inflammatory Factors of Macular Atrophy in Eyes With Neovascular Age-Related Macular Degeneration Treated With Aflibercept. **2021**, 12, 738521 2
- 84 Perspectives on remote patient monitoring with self-operated OCT for management of neovascular age-related macular degeneration. 1-5
- 83 Pacientes no respondedores a anti-VEGF. **2010**, 81-93
- 82 Principales ensayos clínicos con fármacos anti-VEGF en la DMAE exudativa. **2010**, 7-14
- 81 Pautas de seguimiento y retratamiento en pacientes con degeneración macular tratados con ranibizumab (Lucentis®). **2010**, 15-23
- 80 Optische Kohärenztomographie. **2011**, 167-175
- 79 Anti-VEGF-Therapie der AMD: Ergebnisse und Leitlinien. **2011**, 237-251
- 78 Anti-VEGF Monotherapy Treatment Strategies for Neovascular AMD. **2012**, 479-499
- 77 Optische Kohärenztomographie in der Diagnose retinaler Gefäßkrankungen. **2012**, 19-32
- 76 Modalidades de Tratamiento de la Degeneración Macular Asociada a la Edad. **2013**, 41, 2-4
- 75 Neovascular Age-Related Macular Degeneration: Rationale for Current Treatment Guidelines. **2013**, 107-125
- 74 Reliable Therapeutic Modalities To Treat Age-Related Macular Degeneration. **2013**, 41, 2-4
- 73 Respuestas tisulares y vasculares en retinopatía hipertensiva con anticuerpos monoclonales como terapia antiangiogénica. **2013**, 11, 79
- 72 Imagerie de la dégénérescence maculaire exsudative. **2014**, 269-285
- 71 Age-related macular degeneration treatment: current view (literature review). **2014**, 21, 43-50 1
- 70 [Central retinal changes after ranibizumab injection for wet age-related macular degeneration]. **2015**, 131, 60-65 3
- 69 Bevacizumab for neovascular age-related macular degeneration in Chinese patients in a clinical setting. *International Journal of Ophthalmology*, **2016**, 9, 424-30 1.4



68	6-weekly bevacizumab versus 4-weekly ranibizumab for neovascular age-related macular degeneration: a 2-year outcome. <i>International Journal of Ophthalmology</i> , <b>2016</b> , 9, 551-5	1.4	0
67	Factors Associated With Poor Response to Aflibercept After Switching From Ranibizumab or Bevacizumab in Neovascular Age-related Macular Degeneration. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , <b>2016</b> , 47, 458-65	1.4	2
66	The non-Responsiveness to Anti-Vascular Endothelial Growth Factor Agents in the Treatment of Neovascular Age-Related Macular Degeneration. <i>Advances in Ophthalmology &amp; Visual System</i> , <b>2017</b> , 6,	2	
65	Stereological Method in Optical Coherence Tomography for In Vivo Evaluation of Laser-Induced Choroidal Neovascularization. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , <b>2018</b> , 49, e65-e74	1.4	2
64	IMPLICATIONS OF THE MORPHOLOGIC PATTERNS OF TYPE 1 MACULAR NEOVASCULARIZATION ON MACULAR ATROPHY GROWTH ON PATIENTS UNDER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT. <i>Retina</i> , <b>2021</b> , 41, 287-295	3.6	0
63	Visual outcome of Anti-Vascular Endothelial Growth Factor Injections at the University College Hospital, Ibadan.		
62	Posterior Segment. <b>2020</b> , 299-338		
61	Management Strategies for Neovascular AMD. <b>2020</b> , 99-108		
60	TANDEM TRIAL: a factorial randomised controlled trial of dose and review schedule of bevacizumab (Avastin) for neovascular macular degeneration in the East Midlands. <i>BMJ Open Ophthalmology</i> , <b>2020</b> , 5, e000588	3.2	
59	Two different treatment regimens of ranibizumab 0.5 mg for neovascular age-related macular degeneration with or without polypoidal choroidal vasculopathy in Chinese patients: results from the Phase IV, randomized, DRAGON study. <i>Acta Ophthalmologica</i> , <b>2021</b> , 99, e336-e345	3.7	1
58	MANAGEMENT OF RETINAL PIGMENT EPITHELIUM TEAR DURING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. <i>Retina</i> , <b>2021</b> , 41, 671-678	3.6	1
57	Predictors of good visual outcomes in patients with neovascular age-related macular degeneration in daily practice. <i>Journal Francais D'Ophtalmologie</i> , <b>2020</b> , 43, 989-995	0.8	
56	Neovascular AMD. <i>Retina Atlas</i> , <b>2020</b> , 13-28	0	
55	Treatment of Inflammatory Choroidal Neovascular Membranes. <b>2020</b> , 159-168		
54	Comparison of two different treatment regimens' efficacy in neovascular age-related macular degeneration in Turkish population-based on real life data-Bosphorus RWE Study Group. <i>International Journal of Ophthalmology</i> , <b>2020</b> , 13, 104-111	1.4	2
53	Anti-Vascular Endothelial Growth Molecules. <b>2020</b> , 331-341		
52	Long-term Outcomes of Treat and Extend Regimen of Anti-vascular Endothelial Growth Factor in Neovascular Age-related Macular Degeneration. <i>Journal of Ophthalmic and Vision Research</i> , <b>2020</b> , 15, 331-340	1.2	1
51	Temporal pattern of resolution/recurrence of choroidal neovascularization during bevacizumab therapy for wet age-related macular degeneration. <i>International Journal of Ophthalmology</i> , <b>2013</b> , 6, 600-54	1.4	6

50	Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis). <i>Transactions of the American Ophthalmological Society</i> , <b>2014</b> , 112, 160-98		20
49	Effects of three consecutive monthly intravitreal injection of ranibizumab for polypoidal choroidal vasculopathy in Korea. <i>International Journal of Ophthalmology</i> , <b>2015</b> , 8, 315-20	1.4	1
48	Optical Coherence Tomography Monitoring Strategies for A-VEGF-Treated Age-Related Macular Degeneration: An Evidence-Based Analysis. <i>Ontario Health Technology Assessment Series</i> , <b>2014</b> , 14, 1-64	3.1	7
47	Wet age related macular degeneration management and follow-up. <i>Romanian Journal of Ophthalmology</i> , <b>2016</b> , 60, 9-13	1	17
46	Real-Life Data of Patients with Exudative Age-Related Macular Degeneration.. <i>Beyoglu Eye Journal</i> , <b>2021</b> , 6, 304-308	0.1	
45	The Influence of COVID-19 on the Stability of Patients with Neovascular Age-Related Macular Degeneration with Different Treatment Regimens. <i>Advances in Therapy</i> , <b>2021</b> , 1	4.1	2
44	Treat-and-extend regimens of anti-vascular endothelial growth factor therapy for retinal vein occlusions: a systematic review and meta-analysis. <i>Acta Ophthalmologica</i> , <b>2021</b> ,	3.7	0
43	[Results Of The Treatment Of Patients With Exudative Amd During The Covid -19 Pandemic]. <i>Archivos De La Sociedad Espanola De Oftalmologia</i> , <b>2021</b> ,	0.5	1
42	Treatment patterns and outcomes with antivascular endothelial growth factor agents for wet age-related macular degeneration in clinical practice: an analysis of the IRIS Registry. <i>Canadian Journal of Ophthalmology</i> , <b>2021</b> ,	1.4	1
41	Optical coherence tomography angiography for the detection of macular neovascularization-comparison of en face versus cross-sectional view.. <i>Eye</i> , <b>2022</b> ,	4.4	0
40	To investigate treat and extend versus pro re nata regimen in neovascular age-related macular degeneration: results from the IDEM study.. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , <b>2022</b> , 1	3.8	
39	Treatment of macular diseases: an overview of key randomized clinical trials. <i>Rossiiskii Oftalmologicheskii Zhurnal</i> , <b>2022</b> , 14, 137-148	0.3	0
38	Intravitreal anti-VEGF agents âThe way forward. 1, 2-4		
37	Current Management of Diabetic Macular Edema.		1
36	Deep Learning Prediction of Response to Anti-VEGF among Diabetic Macular Edema Patients: Treatment Response Analyzer System (TRAS).. <i>Diagnostics</i> , <b>2022</b> , 12,	3.8	4
35	A Delphi study on the clinical management of age-related macular degeneration.. <i>International Ophthalmology</i> , <b>2022</b> , 1	2.2	0
34	Utilization of deep learning to quantify fluid volume of neovascular age-related macular degeneration patients based on swept-source OCT imaging: The ONTARIO study.. <i>PLoS ONE</i> , <b>2022</b> , 17, e0262111	3.7	0
33	Results of the treatment of patients with exudative AMD during the COVID-19 pandemic.. <i>Archivos De La Sociedad Espanola De Oftalmologia</i> , <b>2022</b> , 97, 184-190	0.1	

32	The efficacy of different anti-vascular endothelial growth factor agents and prognostic biomarkers in monitoring of the treatment for myopic choroidal neovascularization.. <i>International Ophthalmology</i> , <b>2022</b> , 1	2.2	
31	Novel Combined Lidocaine/Povidone Iodine Delivery System for Preintravitreal Injection.. <i>Journal of Ocular Pharmacology and Therapeutics</i> , <b>2022</b> ,	2.6	
30	Clinical outcome and compliance to treatment in patients with CNVM: Our experience. <i>Indian Journal of Clinical and Experimental Ophthalmology</i> , <b>2022</b> , 8, 152-155	0.3	
29	Neovascular Age-Related Macular Degeneration (nAMD): A Review of Emerging Treatment Options.. <i>Clinical Ophthalmology</i> , <b>2022</b> , 16, 917-933	2.5	2
28	One-year outcome of neovascular age-related macular degeneration patients followed-up using different optical coherence tomography modalities.. <i>European Journal of Ophthalmology</i> , <b>2022</b> , 11206721221088260	1.9	
27	Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis.. <i>Eye</i> , <b>2022</b> ,	4.4	2
26	Findings of uncertain significance by optical coherence tomography (OCT) as prognostic factors in neovascular age-related macular degeneration (nAMD) treated with ranibizumab.. <i>International Journal of Retina and Vitreous</i> , <b>2022</b> , 8, 29	2.9	
25	Visual Outcome of Anti-vascular Endothelial Growth Factor Injections at the University College Hospital, Ibadan. <i>Annals of African Medicine</i> , <b>2021</b> , 20, 276-281		
24	Pharmacotherapy of Age-Related Macular Degeneration. <b>2022</b> , 3619-3644		
23	Common retinal disorders. <b>2013</b> , 413-432		
22	Long term results of three anti-vascular endothelial growth factor agents in pachychoroid neovascularopathy.. <i>Cutaneous and Ocular Toxicology</i> , <b>2022</b> , 1-32	1.8	0
21	Review of Intraocular Inflammation After Antivascular Endothelial Growth Factor Agents. <i>International Ophthalmology Clinics</i> , <b>2022</b> , 62, 35-47	1.7	0
20	Relationship between retinal fluid characteristics and vision in neovascular age-related macular degeneration: HARBOR post hoc analysis. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> ,	3.8	1
19	Retrospective analysis of OCT parameters after intravitreal anti-VEGF inhibitors in neovascular AMD patients in a real-world setting. <i>International Ophthalmology</i> ,	2.2	0
18	The impact of retinal fluid tolerance on the outcomes of neovascular age-related macular degeneration treated using aflibercept: A real-world study. <b>2022</b> , 17, e0271999		
17	The Role of Medical Image Modalities and AI in the Early Detection, Diagnosis and Grading of Retinal Diseases: A Survey. <b>2022</b> , 9, 366		
16	Association between structural and functional treatment outcomes in neovascular age-related macular degeneration.		0
15	The Impact of Early Residual Fluid After Anti-Vascular Endothelial Growth Factor Initiation in Patients With Neovascular Age-Related Macular Degeneration: A Meta-Analysis Review. <b>2022</b> , 53, 506-513		0

- 14 Impact of Treating Age-Related Macular Degeneration before Visual Function Is Impaired. **2022**, 11, 5726 ○
- 13 Difference in Lesion Reactivation between Pure Type 2 and Mixed Type 1 and 2 Macular Neovascularization and its Influence on Long-Term Treatment Outcomes. 1-7 ○
- 12 Clinical Phenotypes of Patients with Neovascular Age-Related Macular Degeneration and Poor Response to Aflibercept Treatment. **2022**, 19, 647-657 ○
- 11 Current and Novel Therapeutic Approaches for Treatment of Neovascular Age-Related Macular Degeneration. **2022**, 12, 1629 2
- 10 Effects of intravitreal injection of ranibizumab and aflibercept for branch retinal vein occlusion on the choroid: a retrospective study. **2022**, 22, ○
- 9 Recent trends in anti-vascular endothelial growth factor intravitreal injections: a large claims database study in Japan. 1
- 8 Treatment of neovascular age-related macular degeneration: insights into drug-switch real-world from the Berlin Macular Registry. ○
- 7 Relationship between ganglion cell complex thickness and vision in age-related macular degeneration treated with aflibercept. 112067212211490 ○
- 6 Morphological Macular Changes Under Brolucizumab Treatment for Neovascular Age-Related Macular Degeneration Refractory to Previous Anti-VEGF Treatment Compared with Treatment-Naive Eyes. Volume 17, 769-777 ○
- 5 Brolucizumab in Pretreated Neovascular Age-Related Macular Degeneration: Case Series, Systematic Review, and Meta-Analysis. **2023**, 13, 814 ○
- 4 Common retinal disorders. **2018**, 413-435 ○
- 3 CNV-Net: Segmentation, Classification and Activity Score Measurement of Choroidal Neovascularization (CNV) Using Optical Coherence Tomography Angiography (OCTA). **2023**, 13, 1309 ○
- 2 Enhanced Biosafety of the Sleeping Beauty Transposon System by Using mRNA as Source of Transposase to Efficiently and Stably Transfect Retinal Pigment Epithelial Cells. **2023**, 13, 658 ○
- 1 Meta-Analyses of Two Treatment Regimens for Retinal Vein Occlusion. **2023**, 54, 244-250 ○